

International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 69

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–105) and Recommended (1–66) International Nonproprietary Names can be found in *Cumulative List No. 14, 2011* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 69

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–105) et recommandées (1–66) dans la *Liste récapitulative No. 14, 2011* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 69

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–105) y Recomendadas (1–66) se encuentran reunidas en *Cumulative List No. 14, 2011* (disponible sólo en CD-ROM).

Latin, English, French, Spanish:
Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada

actoxumabum

actoxumab

immunoglobulin G1-kappa, anti-(*Clostridium difficile* toxin A), *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-449) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (228-228":231-231")-bisdisulfide dimer

actoxumab

immunoglobuline G1-kappa, anti-(*Clostridium difficile* toxine A), *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-449) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (228-228":231-231")-bisdisulfure

actoxumab

immunoglobulina G1-kappa, anti-(toxina A de *Clostridium difficile*), anticuerpo monoclonal de *Homo sapiens* ;
cadena pesada gamma1 (1-449) [*Homo sapiens* VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [*Homo sapiens* V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (228-228":231-231")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVQSGAE	VKKSAGESLKI	SCKGSQYSFT	SYWIGWVRQM	PGKGLEWMI	50
FYPGDSSTRY	SPSPQQQVTI	SADKSVNTAY	LQWSSLKASD	TAMYCARRR	100
NWGNAFDIWG	QGTMTVTSSA	STKGPVSFPL	APSSKSTSGG	TAALGCLVKD	150
YFPEPVTWSW	NSGALTSGVH	TFFPAVLQSSG	LYSLSSVVTV	PSSSLGTQTY	200
ICNVNHKPSN	TKVDRKVEPK	SCDKTHTCPP	CPAPELLGGP	SVFLFPPKPK	250
DTLMISRTP	VTCVVDVSH	EDPEVKFNWY	VDGVEVHNAK	TKPREEQYNS	300
TYRVVSVLTV	LHQDWLNGKE	YKCKVSNKAL	PAPIEKTISK	AKGQPREPQV	350
YTLPPSREEM	TKNQVSLTCL	VKGFPYSDIA	VEWESNGQPE	NNYKTTTPVL	400
DSDGSFFFLYS	KLTVDKSRWQ	QGNVFCSSVM	HEALHNHYTQ	KSLSLSPGK	449

Light chain / Chaîne légère / Cadena ligera

EIVLTQSPGT	LSLSPGERAT	LSCRASQSVS	SSYLAWYQQK	PGQAPRLLIY	50
GASSRATGIP	DRFSGSGSGT	DFTLTISRLE	PDFFAVYCCQ	YQGSSTWTFG	100
QGTKVEIKRT	VAAPSVFIFP	PSDEQLKSGT	ASVVCLLNPF	YPREAKVQWK	150
VDNALQSGNS	QESVTEQDSK	DSTYLSSTL	TLSKADYEKH	KVYACEVTHQ	200
GLSSPVTKSF	NRGEC				215


Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H	22-96	146-202	263-323	369-427
	22"-96"	146"-202"	263"-323"	369"-427"
Intra-L	23'-89'	135'-195'		
	23'''-89'''	135'''-195'''		
Inter-H-L	222-215'	222"-215'''		
Inter-H-H	228-228"	231-231"		

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
299, 299"

aladorianum	
aladorian	(7-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5 <i>H</i>)-yl)oxoacetic acid
aladorian	acide (7-méthoxy-2,3-dihydro-1,4-benzothiazépin-4(5 <i>H</i>)-yl)oxoacétique
aladorián	ácido (7- metoxi-2,3-dihidro-1,4-benzotiazepin-4(5 <i>H</i>)-il)oxoacético

C₁₂H₁₃NO₄S

alirocumabum #	
alirocumab	immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> PCSK9 (proprotein convertase subtilisin/kexin type 9)], <i>Homo sapiens</i> monoclonal antibody; gamma1 heavy chain (1-447) [<i>Homo sapiens</i> VH (IGHV3-23*04 (89.80%) -(IGHD)-IGHJ2*01 [8.8.11] (1-118) -IGHG1*01 CHS K2>del (119-447)), (221-220')-disulfide with kappa light chain (1'-220') [<i>Homo sapiens</i> V-KAPPA (IGKV4-1*01 (94.10%) -IGKJ2*01 [12.3.9] (1'-113') -IGKC*01 (114'-220'))]; (227-227":230-230")-bisdisulfide dimer
alirocumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> PCSK9 (proprotéine convertase subtilisine/kexine type 9)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-447) [<i>Homo sapiens</i> VH (IGHV3-23*04 (89.80%) -(IGHD)-IGHJ2*01 [8.8.11] (1-118) -IGHG1*01 CHS K2>del (119-447)), (221-220')-disulfure avec la chaîne légère kappa (1'-220') [<i>Homo sapiens</i> V-KAPPA (IGKV4-1*01 (94.10%) -IGKJ2*01 [12.3.9] (1'-113') -IGKC*01 (114'-220'))]; dimère (227-227":230-230")-bisdisulfure
alirocumab	inmunoglobulina G1-kappa, anti-[PCSK9 de <i>Homo sapiens</i> (proteína convertasa subtilisina/kexina tipo 9)], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena pesada gamma1 (1-447) [<i>Homo sapiens</i> VH (IGHV3-23*04 (89.80%) -(IGHD)-IGHJ2*01 [8.8.11] (1-118) -IGHG1*01 CHS K2>del (119-447)), (221-220')-disulfuro con la cadena ligera kappa (1'-220') [<i>Homo sapiens</i> V-KAPPA (IGKV4-1*01 (94.10%) -IGKJ2*01 [12.3.9] (1'-113') -IGKC*01 (114'-220'))]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG LVQPGGSLRL SCAASGFTFN NYAMNWRVQA PGKGLDWVST 50
 ISGSGGTNY ADSVKGRFII SRDSSKHTLY LQMNSLRAED TAVYYCAKDS 100
 NWGFDLWGR GTLVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
 FPEFVTVSWN SGALTSVHT FPAVLQSSGL YSLSSVTVF SSSLGTQTYI 200
 CNVNHKPSNT KVDKKEPKS CDKTHTCPPC PAPELLGGPS VFLFPPKPKD 250
 TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQNST 300
 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
 TLPFSSRDELTKNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTPVLD 400
 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPG 447

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS LAVSLGERAT INCKSSQSVL YRSNNRNLFLG WYQQKPGQPP 50
 NLLIYWASTR ESGVPRDFSG SGSGTDFTLT ISSLQAEDVA VYYCQQYTT 100
 PYTFGQGTKL EIKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150
 KVQWKVDNAL QSGNSQESVT EQDSKDSSTYS LSSTLTLSKA DYEKHKVYAC 200
 EVTHQGLSSP VTKSFNRGEC 220

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 145-201 262-322 368-426
 22"-96" 145"-201" 262"-322" 368"-426"
 Intra-L 23'-94' 140'-200'
 23"-94" 140"-200"
 Inter-H-L 221-220' 221"-220"
 Inter-H-H 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 298, 298"

antithrombin gamma #

antithrombin gamma

afucosylated antithrombin; human antithrombin-III (ATIII, serpin C1) expressed in fucosyl transferase-negative Chinese Hamster Ovary (CHO) cells (glycoform gamma)

antithrombine gamma

antithrombine afucosylée; antithrombine-III humaine (ATIII, serpine C1) obtenue à partir de culture de cellules ovariennes d'hamster chinois (CHO) n'exprimant pas la fucosyl transférase (glycoforme gamma)

antitrombina gamma


antitrombina afucosilada; antitrombina-III humana (ATIII, serpina C1) obtenida a partir de cultivo de células ováricas de hamster chino (CHO) que no expresan la fucosil transferasa (glicoforma gamma)

HGSPVDICTA KPRDIPMNPM CIYRSPEKKA TEDEGSEQKI PEATNRRVWE 50
 LSKANSRFAT TFYQHLADSK NDNNDNIFLSP LSISTAFAMT KLGACNDTLQ 100
 QLMVEVFKFDT ISEKTSQIHF FFFAKLNCRL YRKANKSSKL VSANRFLGDK 150
 SLTFNETYQD ISELVYGAKL QPLDFKENAE QSRAAINKWV SNKTEGRITD 200
 VIPSEAINEL TVLVLVNTIY FKGLKSKSFS PENTRKELFY KADGESCSAS 250
 MMYQEGKFRY RRVAEQTQVL ELFFKGGDIT MVLILPKPEK SLAKVEKELT 300
 PEVLQEWLDE LEEMMLVVHM PRFRIEDGFS LKEQLQDMGL VDLFSPEKSK 350
 LFGIVAEGRD DLYVSDAFHK AFLEVNEEGS EAAASTAVVI AGRSLNPNRV 400
 TFKANRPFVLV FIREVPLNTI IFMGRVANPC VK 432

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

8-128 21-95 247-430



Modified residue / Résidu modifié / Residuo modificado



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-96 Asn-135 Asn-155 Asn-192

α -Sia→3-β-Gal→3-β-Gl-N→2-α-Man→6-β-Man→4-β-Gl-N→4-β-Gl-N→N
 α -Sia→3-β-Gal→3-β-Gl-N→2-α-Man→3-β-Man→4-β-Gl-N→4-β-Gl-N→N

asudemotidum	
asudemotide	human DEP domain-containing protein 1A-(294-302)-peptide
asudémotide	protéine 1A humaine contenant le domaine DEP-(294-302)-peptide
asudemotida	proteína 1A humana que contiene el dominio DEP-(294-302)-péptido
	$C_{58}H_{80}N_{10}O_{17}$
	H-Glu-Tyr-Tyr-Glu-Leu-Phe-Val-Asn-Ile-OH
auriclosenum	
auriclosene	2-(dichloroamino)-2-methylpropane-1-sulfonic acid
auriclosène	acide 2-(dichloroamino)-2-méthylpropane-1-sulfonique
auricloseno	ácido 2-(dicloroamino)-2-metilpropano-1-sulfónico
	$C_4H_9Cl_2NO_3S$
	
avatrombopagum	
avatrombopag	1-(3-chloro-5-[[4-(4-chlorothiophen-2-yl)-5-(4-cyclohexylpiperazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl)piperidine-4-carboxylic acid
avatrombopag	acide 1-(3-chloro-5-[[4-(4-chlorothiophén-2-yl)-5-(4-cyclohexylpipérazin-1-yl)-1,3-thiazol-2-yl]carbamoyl]pyridin-2-yl)pipéridine-4-carboxylique
avatrombopag	ácido 1-(3-cloro-5-[[5-(4-ciclohexilpiperazin-1-il)-4-(4-clorotiofen-2-il)-1,3-tiazol-2-il]carbamoil]piridin-2-il)piperidina-4-carboxílico
	$C_{29}H_{34}Cl_2N_6O_3S_2$
	
balugrastimum #	
balugrastim	human serum albumin (585 residues) fusion protein with des-(1-alanine,37-valine,38-serine,39-glutamic acid)-human granulocyte colony-stimulating factor (pluripoietin)
balugrastim	albumine sérique humaine (585 résidus) protéine de fusion avec le dès-(1-alanine,37-valine,38-sérine,39-acide glutamique)-facteur de stimulation des colonies de granulocytes humain (pluripoéitine)
balugrastim	albumina sérica humana (585 residuos) proteína de fusión con el dès-(1-alanina,37-valina,38-serina,39-ácido glutámico)-factor humano estimulante de las colonias de granulocitos (pluripoyetina)

DAHKSEVAHR FKDLGEENFK ALVLIIFAQY LQQCPFEDHV KLVNEVTEFA 50
 KTCVADESAE NCDKSLHTLF GDKLCTVATL RETYGMADC CAKQEPERNE 100
 CFLQHKDDNP NLPRLVRPEV DVMCTAFHDN BETFLKKYLY EIARRHPYFY 150
 APELLFFAKR YKAAFECCQ AADKAACLLP KLDELREDEGK ASSAKQRLKC 200
 ASLQKFGERA FKAAVARLS QRFPKAEFAE VSKLVTDLTK VHTECCHGDL 250
 LECADDRADL AKYICENQDS ISSKLECCCE KPLLEKSHCI AEVENDEMPA 300
 DLPSLAADFV ESKDVCNYA EAKDVLGMF LYEYARRHFD YSVVLLRLA 350
 KTYETTLEKC CAAADPHECY AKVFDEFKPL VEEFQNLIKQ NCELFEQLGE 400
 YKFNALLVR YTKKVPQVST PTLVEVSRNL GKVSKCCKH PEAKRMPCAE 450
 DYLSVVLNQL CVLHEKTPVS DRVTKCCTES LVNRRPCFSA LEVDETYVPK 500
 EFNAETFFTH ADICTLSEKE RQIKKQTALV ELVKHKPKAT KEQLKAVMDD 550
 FAFVVEKCK ADDKETCFAE EGKKLVAASQ AALGLTPLGP ASSLPQSFL 600
 KCLEQVRKIQ GDGAALQEKL CATYKLCHPE ELVLLGHSLG IPWAPLSSCP 650
 SQALQLAGCL SQLHSGFLY QGLLQALEGI SPELGPPLDT LQLDVADFAT 700
 TIWQQMELG MAPALQPTQG AMPAFASAFQ RRAGGVLVAS HLQSFLEVS 750
 RVLRLHAQP 759

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 53-62 75-91 90-101 124-169 168-177 200-246 245-253
 265-279 278-289 316-361 360-369 392-438 437-448 461-477
 476-487 514-559 558-567 621-627 649-659

baricitinibum

baricitinib


{1-(ethanesulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetid-3-yl}ethanenitrile

baricitinib

{1-(éthanesulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azétidin-3-yl}éthanenitrile

baricitinib

{1-(etanosulfonyl)-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]azetid-3-il}etanonitrilo

C₁₆H₁₇N₇O₂S**bevenopranum**

bevenopran


5-[2-methoxy-4-({[2-(oxan-4-yl)ethyl]amino}methyl)phenoxy]pyrazine-2-carboxamide

bévénofran



5-[2-méthoxy-4-({[2-(oxan-4-yl)éthyl]amino}méthyl)phénoxy]pyrazine-2-carboxamide

bevenoprán

5-[2-metoxi-4-({[2-(oxan-4-il)etil]amino}metil)fenoksi]pirazina-2-carboxamida

C₂₀H₂₆N₄O₄

bezlotoxumabum # bezlotoxumab	immunoglobulin G1-kappa, anti-[<i>Clostridium difficile</i> toxin B)], <i>Homo sapiens</i> monoclonal antibody; gamma1 heavy chain (1-449) [<i>Homo sapiens</i> VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfide with kappa light chain (1'-215') [<i>Homo sapiens</i> V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; (228-228":231-231")-bisdisulfide dimer
bezlotoxumab	immunoglobuline G1-kappa, anti-[<i>Clostridium difficile</i> toxine B)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-449) [<i>Homo sapiens</i> VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfure avec la chaîne légère kappa (1'-215') [<i>Homo sapiens</i> V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dimère (228-228":231-231")-bisdisulfure
bezlotoxumab	immunoglobulina G1-kappa, anti-[toxina B de <i>Clostridium difficile</i>)], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena pesada gamma1 (1-449) [<i>Homo sapiens</i> VH (IGHV5-51*01 (94.90%) -(IGHD)-IGHJ3*02) [8.8.12] (1-119) -IGHG1*03 (120-449)], (222-215')-disulfuro con la cadena ligera kappa (1'-215') [<i>Homo sapiens</i> V-KAPPA (IGKV3-20*01 (100.00%) -IGKJ1*01) [7.3.9] (1'-108') -IGKC*01 (109'-215')]; dímero (228-228":231-231")-bisdisulfuro
	Heavy chain / Chaîne lourde / Cadena pesada EVQLVQSGAE VKKSGESLKI SCKGSGYSFT SYWIGWVRQM PGKGLEWMI 50 FYPGDSSTRY SPSFQGQVTI SADKSVNTAY LQWSSLKASD TAMYYCARRR 100 NWGNAFDIWG QGTMVTVSSA STKGPSVFPPL APSSKSTSGG TAALGCLVKD 150 YFPEPVTVSW NSGALTSGVH TFFAVLQSSG LYSLSVVTV PSSSLGTQTY 200 ICNVNHKPSN TKVDRKVEPK SCDKTHTCPP CPAPPELLGGP SVFLFPPKPK 250 DTLMISRTPE VTCVVDVSH EDEKVKFNWY VDGVEVHNAK TKPREEQYNS 300 TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350 YTLPPSREEM TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTPPVV 400 DSDGSFFLYS KLTVDKSRWQ QGNVPSCSVM HEALHNHYTQ KSLSLSPGK 449
	Light chain / Chaîne légère / Cadena ligera EIVLTQSEPT LSLSPGERAT LSCRASQSVS SSVLAWYQQK PGQAPRLLIY 50 GASSRATGIP DRFSGSGSGT DFTLTISRLE PEDFAVYYCQ QYGSSTWTFG 100 QGTEKVEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNFF YPREAKVQWK 150 VDNALQSGNS QESVTEQDSK DSTYLSLSTL TLSKADYEKH KYVACEVTHQ 200 GLSSPVTKSF NRGEC 215
	Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 146-202 263-323 369-427 22"-96" 146"-202" 263"-323" 369"-427" Intra-L 23'-89' 135'-195' 23'"-89'" 135'"-195'" Inter-H-L 222-215' 222"-215" Inter-H-H 228-228" 231-231"
	N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 299, 299"
birinapantum birinapant	<i>N,N'</i> -[(6,6'-difluoro[1 <i>H</i> ,1' <i>H</i> -2,2'-biindole]-3,3'-diyl)bis(methylene[(2 <i>R</i> ,4 <i>S</i>)-4-hydroxypyrrolidine-2,1-diyl]][(2 <i>S</i>)-1-oxobutane-1,2-diyl] bis[(2 <i>S</i>)-2-(methylamino)propanamide]
birinapant	<i>N,N'</i> -[(6,6'-difluoro[1 <i>H</i> ,1' <i>H</i> -2,2'-biindole]-3,3'-diyl)bis(méthylène[(2 <i>R</i> ,4 <i>S</i>)-4-hydroxypyrrolidine-2,1-diyl]][(2 <i>S</i>)-1-oxobutane-1,2-diyl]]bis[(2 <i>S</i>)-2-(méthylamino)propanamide]
birinapant	<i>N,N'</i> -[(6,6'-difluoro[1 <i>H</i> ,1' <i>H</i> -2,2'-biindol]-3,3'-diil)bis(metileno[(2 <i>R</i> ,4 <i>S</i>)-4-hidroxiporrolidina-2,1-diil]][(2 <i>S</i>)-1-oxobutano-1,2-diilo]bis[(2 <i>S</i>)-2-(metilamino)propanamida]




blisibimodum #
blisibimod

B-cell activating factor (BAFF)-binding peptide fragment/human IgG1 Fc fusion protein;
glycyl-L-cysteinyl-L-lysyl-L-tryptophyl-[[29-isoleucine(V>I),30-lysine(R>K),31-glutamine(H>Q)]human tumor necrosis factor receptor superfamily member 13C (BAFF receptor, CD268)-(26-31)-peptidyl]-L-tryptophyl-L-valyl-L-cysteinyl-L-aspartyl-L-prolyl-L-leucylglycyl-L-serylglycyl-L-seryl-L-alanyl-L-threonylglycylglycyl-L-serylglycyl-L-seryl-L-threonyl-L-alanyl-L-seryl-L-serylglycyl-L-serylglycyl-L-seryl-L-alanyl-L-threonyl-L-histidyl-L-methionyl-L-leucyl-L-prolylglycyl-L-cysteinyl-L-lysyl-L-tryptophyl-[[29-isoleucine(V>I),30-lysine(R>K),31-glutamine(H>Q)]human tumor necrosis factor receptor superfamily member 13C (BAFF receptor, CD268)-(26-31)-peptidyl]-L-tryptophyl-L-valyl-L-cysteinyl-L-aspartyl-L-prolyl-L-leucylpentaglycyl-L-valyl-(human immunoglobulin heavy constant gamma 1 Fc-(6-232)-peptide) dimer (69-69':72-72')-bisdisulfide

blisibimod

protéine de fusion entre le fragment Fc de l'immunoglobuline G1 humaine et un fragment du peptide se liant au facteur d'activation des cellules B (BAFF);
glycyl-L-cystéinyl-L-lysyl-L-tryptophyl-[[29-isoleucine(V>I),30-lysine(R>K),31-glutamine(H>Q)]membre 13C de la superfamille des récepteurs humains du facteur de nécrose tumorale (TNF) (récepteur du BAFF, CD268)-(26-31)-peptidyl]-L-tryptophyl-L-valyl-L-cystéinyl-L-aspartyl-L-prolyl-L-leucylglycyl-L-serylglycyl-L-séryl-L-alanyl-L-thréonylglycylglycyl-L-sérylglycyl-L-séryl-L-thréonyl-L-alanyl-L-séryl-L-sérylglycyl-L-sérylglycyl-L-séryl-L-alanyl-L-thréonyl-L-histidyl-L-méthionyl-L-leucyl-L-prolylglycyl-L-cystéinyl-L-lysyl-L-tryptophyl-[[29-isoleucine(V>I),30-lysine(R>K),31-glutamine(H>Q)]membre 13C de la superfamille des récepteurs humains du TNF (récepteur du BAFF, CD268)-(26-31)-peptidyl]-L-tryptophyl-L-valyl-L-cystéinyl-L-aspartyl-L-prolyl-L-leucylpentaglycyl-L-valyl-(fragment Fc de la chaîne lourde gamma 1 de l'immunoglobuline humaine-(6-232)-peptide), (69-69':72-72')-bisdisulfure du dimère

blisibimod	<p>proteína de fusión entre el fragmento Fc de la inmunoglobulina G1 humana y un fragmento del péptido que se une al factor de activación de las células B (BAFF); glicil-L-cisteinil-L-lisil-L-triptofil-[[29-isoleucina(V>I),30-lisina(R>K),31-glutamina(H>Q)]miembro 13C de la superfamilia de receptores humanos del factor de necrosis tumoral (TNF) (receptor del BAFF, CD268)-(26-31)-peptidil]-L-triptofil-L-valil-L-cisteinil-L-aspartil-L-proilil-L-leucilglicil-L-serilglicil-L-seril-L-alanil-L-treonilglicilglicil-L-serilglicil-L-seril-L-treonil-L-alanil-L-seril-L-serilglicil-L-serilglicil-L-seril-L-alanil-L-treonil-L-histidil-L-metionil-L-leucil-L-proililglicil-L-cisteinil-L-lisil-L-triptofil-[[29-isoleucina(V>I),30-lisina(R>K),31-glutamina(H>Q)]miembro 13C de la superfamilia de receptores humanos del TNF (receptor del BAFF, CD268)-(26-31)-peptidil]-L-triptofil-L-valil-L-cisteinil-L-aspartil-L-proilil-L-leucilpentaglicil-L-valil-(fragmento Fc de la cadena pesada gamma 1 de la inmunoglobulina humana-(6-232)-péptido), (69-69':72-72')-bisdisulfuro del dímero</p> <p>Monomer / Monomère / Monómero GCKWDLLIKQ WVCDDLPLSGS ATGGSGSTAS SGSGSATHML PGCKWDLLIK 50 QWVCDPLGGG GGVDKTHTCP PCPAPPELLGG PSVFLFPPKP KDTLMISRTP 100 EVTCCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT 150 VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE 200 LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTFPV LDSGGSFFLY 250 SKLTVDKSRW QQGNVFCSCV MHEALHNHYT QKSLSLSPGK 290</p> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro 2-13 2'-13' 43-54 43'-54' 69-69' 72-72' 104-164 104'-164' 210-268 210'-268'</p>
burlulipasum # burlulipase	<p>lipase (triacylglycerol lipase, EC-3.1.1.3) which amino acids sequence is common to <i>Burkholderia plantarii</i> and <i>Burkholderia glumae</i></p>
burlulipase	<p>lipase (triacylglycérol lipase, EC-3.1.1.3) dont la séquence d'acides aminés est commune à <i>Burkholderia plantarii</i> et <i>Burkholderia glumae</i></p>
burlulipasa	<p>lipasa (triacilglicerol lipasa, EC-3.1.1.3) cuya secuencia de aminoácidos es comuna a <i>Burkholderia plantarii</i> y <i>Burkholderia glumae</i></p> <p>ADTYAATRYP VILVHGLAGT DKFANVVDYW YGIQSDLQSH GAKVYVANLS 50 GFQSDDGPNR RGEQLLAYVK QVLAATGATK VNLIHGSQGG LTRSRYVAAVA 100 PQLVASVTTI GTPHRGSEFA DFVQDVLKTD PTGLSSTVIA AFVNVFGLTV 150 SSSHNTDQDA LAALRTLTTA QTATYNRNFP SAGLGAPGSC QTGAATETVG 200 GSQHLLYSWG GTAIQPTSTV LGVTGATDTS TGTLDVANVT DPSTLALLAT 250 GAVMINRASG QNDGLVSRCS SLFGQVISTS YHWNHLDEIN QLLGVRGANA 300 EDPVAVIRTH VNRLKLQGV 319</p> <p>Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro 190-269</p>
cebranopadolum cebranopadol	<p><i>trans</i>-6'-fluoro-<i>N,N</i>-dimethyl-4-phenyl-4',9'-dihydro-3'<i>H</i>-spiro[cyclohexane-1,1'-pyrano[3,4-<i>b</i>]indol]-4-amine</p>
cébranopadol	<p><i>trans</i>-6'-fluoro-<i>N,N</i>-diméthyl-4-phényl-4',9'-dihydro-3'<i>H</i>-spiro[cyclohexane-1,1'-pyrano[3,4-<i>b</i>]indol]-4-amine</p>
cebranopadol	<p><i>trans</i>-4-fenil-6'-fluoro-<i>N,N</i>-dimetil-4',9'-dihidro-3'<i>H</i>-espiro[ciclohexano-1,1'-pirano[3,4-<i>b</i>]indol]-4-amina</p>

C₂₄H₂₇FN₂O

cindunistatum

cindunistat


S-[2-(acetimidoylamino)ethyl]-2-methyl-L-cysteine

cindunistat

S-[2-(acétimidoylamino)éthyl]-2-méthyl-L-cystéine

cindunistat

S-[2-(acetimidoilamino)etil]-2-metil-L-cisteina

C₈H₁₇N₃O₂S

clazakizumabum #

clazakizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL6 (interleukin 6, IL-6)], humanized monoclonal antibody;
 gamma1 heavy chain (1-450) [humanized VH (*Homo sapiens*IGHV3-66*01 (83.50%) -(IGHD)-IGHJ3*02 M123>L (115)) [8.8.14] (1-120) -*Homo sapiens*IGHG1*03 CH2 N84.4>A (300) (121-450)], (223-217')-disulfide with kappa light chain (1'-217') [humanized V-KAPPA (*Homo sapiens*IGKV1-39*01 (89.10%) -IGKJ4*01) [6.3.12] (1'-110') -*Homo sapiens*IGKC*01 (111'-217')]; (229-229":232-232")-bisdisulfide dimer

clazakizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL6 (interleukine 6, IL-6)], anticorps monoclonal humanisé;
 chaîne lourde gamma1 (1-450) [VH humanisé (*Homo sapiens*IGHV3-66*01 (83.50%) -(IGHD)-IGHJ3*02 M123>L (115)) [8.8.14] (1-120) -*Homo sapiens*IGHG1*03 CH2 N84.4>A (300) (121-450)], (223-217')-disulfure avec la chaîne légère kappa (1'-217') [V-KAPPA humanisé (*Homo sapiens*IGKV1-39*01 (89.10%) -IGKJ4*01) [6.3.12] (1'-110') -*Homo sapiens*IGKC*01 (111'-217')]; dimère (229-229":232-232")-bisdisulfure

clazakizumab

immunoglobulina G1-kappa, anti-[IL6 de *Homo sapiens* (interleukina 6, IL-6)], anticuerpo monoclonal humanizado;
 cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens*IGHV3-66*01 (83.50%) -(IGHD)-IGHJ3*02 M123>L (115)) [8.8.14] (1-120) -*Homo sapiens*IGHG1*03 CH2 N84.4>A (300) (121-450)], (223-217')-disulfuro con la cadena ligera kappa (1'-217') [V-KAPPA humanizado (*Homo sapiens*IGKV1-39*01 (89.10%) -IGKJ4*01) [6.3.12] (1'-110') -*Homo sapiens*IGKC*01 (111'-217')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGG LVQPFGSLRL SCAASGFSLN NYYVTWVWQA PGKGLEWVGI 50
 IYGSDEETAYA TSAIGRFTIS RDNSKNTLYL QMNSLRAEDT AVYYCARDSS 100
 SDWDAKFNWV GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
 DYFPEPVTVS WNSGALTSV HTPFAVLQSS GLYSLSSVVT VPSSSLGTQT 200
 YICNVNHFPS NTKVDKRVPE KSCDKHTTCE PCPAPPELLGG PSVFLFPPKP 250
 KDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYA 300
 STYRVVSVLT VLGQDWNLNGK EYKCKVSNKA LPAPIEKTIS KARGQPREPQ 350
 VYTLPPSREE MTKNQVSLTCLVKGFYPSDI AVEWESNGQP ENNYKTTPEV 400
 LDDSGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligera
 AIQMTQSPSS LSASVGRVITTCQASQSN NLSWYQKPK GKAPKLLIYR 50
 ASTLASGVPS RFGSGSGSDTFTLTISLQP DDEATYYCQQ GYSLRNIDNA 100
 FGGGTKEVLEK RTVAAPSDFI PPSDEQLKSTASVVCCLLN NFYPREAKVQ 150
 WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE KHKVYACEVT 200
 HQGLSSPVTK SFNRGEC 217

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H 22-95 147-203 264-324 370-428
 22'-95" 147"-203" 264"-324" 370"-428"
 Intra-L 23'-88" 137"-197"
 23"-88" 137"-197"
 Inter-H-L 223-217' 223"-217"
 Inter-H-H 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 None : H CH2 N84.4>A

cobimetinibum

cobimetinib


[3,4-difluoro-2-(2-fluoro-4-iodoanilino)fenil]{3-hidroxi-3-[(2S)-piperidin-2-yl]azetidín-1-yl}metanona

cobimétinib

[3,4-difluoro-2-(2-fluoro-4-iodoanilino)phényl]{3-hidroxi-3-[(2S)-pipéridin-2-yl]azétidín-1-yl}méthanone

cobimetinib

[3,4-difluoro-2-(2-fluoro-4-iodoanilino)fenil]{3-hidroxi-3-[(2S)-piperidin-2-yl]azetidín-1-yl}metanona

C₂₁H₂₁F₃IN₃O₂**crisantaspasum #**

crisantaspase

L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase) *Erwinia chrysanthemi* tetramer α_4

crisantaspase

L-asparaginase (EC 3.5.1.1, L-asparagine amidohydrolase) *Erwinia chrysanthemi*, tétramère α_4

crisantaspasa

L-asparaginasa (EC 3.5.1.1, L-asparagina amidohidrolasa) de *Erwinia chrysanthemi*, tetrámero α_4

C₁₅₄₆H₂₅₁₀N₄₃₂O₄₇₆S₉ (monomer)

Monomer / Monomère / Monómero

ADKLPNIVIL ATGGTIAGSA ATGTQTTGK AGALGVDTLI AVPEVKKLA 50
 NVKGEQFSNM ASENMTGDV LKLSQRVNEL LARDDVDGVV ITHGTDVVEE 100
 SAYFLHLTVK SDKPVVAVAA MRPATAISAD GPMNLLEAVR VAGDKQSRGR 150
 GVMVLLNDRI GSARYITKTN ASTLDTFFKAN EGYLVGVIIG NRIYYQNRID 200
 KLHTTRSVFD VRGLTSLPKV DILYGYQDDP EYLYDAAIQH GVKGIYVAGM 250
 GAGSVSVRGI AGMRKAMEKG VVIRSTRTG NGIVPPDEEL PGLVSDSLNP 300
 AHARILLMLA LTRTSDPKVI QEYFHTY 327

dactolisibum


dactolisib

2-methyl-2-(4-{3-methyl-2-oxo-8-(quinolin-3-yl)-
2,3-dihydroimidazo[4,5-c]quinolin-1-yl}phenyl)propanenitrile

dactolisib

2-méthyl-2-(4-[3-méthyl-2-oxo-8-(quinoléin-3-yl)-
2,3-dihydroimidazo[4,5-c]quinoléin-1-yl]phényl)propanenitrile

dactolisib

2-metil-2-(4-{3-metil-2-oxo-8-(quinolin-3-il)-2,3-dihidroimidazo[4,5-
c]quinolin-1-il}fenil)propanonitriloC₃₀H₂₃N₅O**danirixinum**


danirixin

1-(4-chloro-2-hydroxy-3-[[[(3S)-piperidine-3-sulfonyl]phenyl]-
3-(3-fluoro-2-methylphenyl)urea

danirixine

1-(4-chloro-2-hydroxy-3-[[[(3S)-pipéridine-3-sulfonyl]phényl]-
3-(3-fluoro-2-méthylphényl)urée

danirixina

1-(4-cloro-2-hidroxi-3-[[[(3S)-piperidina-3-sulfonil]fenil]-3-(3-fluoro-
2-metilfenil)ureaC₁₉H₂₁ClFN₃O₄S**demcizumabum #**

demcizumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* DLL4 (delta-like 4)],
humanized monoclonal antibody;
gamma2 heavy chain (1-444) [humanized VH (*Homo sapiens*
IGHV1-18*01 (85.70%) -(IGHD)-IGHJ6*01 T123>L (114) [8.8.12] (1-
119) -*Homo sapiens* IGHG2*01 CHS K2>del (120-444)], (133-218)-
disulfide with kappa light chain (1'-218') [humanized V-KAPPA
(*Homo sapiens* IGKV4-1*01 (76.20%) -IGKJ1*01 Q120>G (104))
[10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218'); (221-
221":222-222":225-225":228-228")-tetrakisdisulfide dimer

demcizumab immunoglobuline G2-kappa, anti-[*Homo sapiens* DLL4 (delta-like 4)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-444) [VH humanisé (*Homo sapiens* IGHV1-18*01 (85.70%) -(IGHD)-IGHJ6*01 T123>L (114) [8.8.12] (1-119) -*Homo sapiens* IGHG2*01 CHS K2>del (120-444)], (133-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (76.20%) -IGKJ1*01 Q120>G (104)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimère (221-221":222-222":225-225":228-228")-tétrakisdisulfure

demcizumab inmunoglobulina G2-kappa, anti-[DLL4 (delta-like 4) de *Homo sapiens*], anticuerpo monoclonal humanizado; cadena pesada gamma2 (1-444) [VH humanizado (*Homo sapiens* IGHV1-18*01 (85.70%) -(IGHD)-IGHJ6*01 T123>L (114) [8.8.12] (1-119) -*Homo sapiens* IGHG2*01 CHS K2>del (120-444)], (133-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (76.20%) -IGKJ1*01 Q120>G (104)) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dímero (221-221":222-222":225-225":228-228")-tetraakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKI SCKASGYSFT AYYIHHVKQA PGQGLEWIGY 50
 ISSYNGATNY NQKFKGRVTF TTDSTSTAY MELRSLRSD TAVYYCARDY 100
 DYDVGMDYWG QGTLVTVSSA STKGPSVFPL APCSRSTSES TAALGCLVKD 150
 YFPEPVTVSW NSGALTSGVH TFFAVLQSSG LYSLSVTVV PPSNFGTQTY 200
 TCNVDHKKPSN TKVDKTVVERK CCVECPPCPA PPVAGPSVFL FPPKPKDTLM 250
 ISRTPEVTCV VVDVSHEDPE VQFNWYVDGV EVHNAKTKPR EEQFNSTFRV 300
 VSVLTVVHQD WLNKKEYKCK VSNKGLPAPI EKTISKTKGQ PREPQVYTLR 350
 PSREEMTKNQ VSLTCLVKG FYPSDIAVEWE SNGQPENNYK TTPPMLDSDG 400
 SFLYLSKLTV DKSRWQQGNV FSCSVMEAL HNHYTQKSL S LSPG 444

Light chain / Chaîne légère / Cadena ligera

DIIVTQSPDS LAVSLGERAT ISCRASESVD NYGISFMKWF QQKPGQPPL 50
 LIYAASNQGS GVPDRFSGSG SCTDFTLTIS SLQAEDVAVY YCQQSKEVPW 100
 TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
 QWKVDNALQS GNSQESVTEQ DSKDSTYSL S TLTLSKADY EKHKVYACEV 200
 THQGLSSPVT KSFNRGEC 218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 259-319 365-423
 22"-96" 146"-202" 259"-319" 365"-423"
 Intra-L 23"-92" 138"-198"
 23"-92" 138"-198"
 Inter-H-L 133-218" 133"-218"
 Inter-H-H 221-221" 222-222" 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 295, 295"

elbimilastum

elbimilast


N-(3,5-dichloropyridin-4-yl)-2-{1-[(4-fluorophenyl)methyl]-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl}-2-oxoacetamide

elbimilast

N-(3,5-dichloropyridin-4-yl)-2-{1-[(4-fluorophényl)méthyl]-1*H*-pyrrolo[2,3-*b*]pyridin-3-yl}-2-oxoacétamide

elbimilast

N-(3,5-dicloropiridin-4-il)-2-{1-[(4-fluorofenil)metil]-1*H*-pirrolo[2,3-*b*]piridin-3-il}-2-oxoacetamida

C₂₁H₁₃Cl₂FN₄O₂

elubrixinum

elubrixin


1-(2-chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-(piperazine-1-sulfonyl)phenyl]urea

élubrixine

1-(2-chloro-3-fluorophényl)-3-[4-chloro-2-hydroxy-3-(pipérazine-1-sulfonyl)phényl]urée

elubrixina

1-(2-cloro-3-fluorofenil)-3-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonyl)fenil]urea

C₁₇H₁₇Cl₂FN₄O₄S**empegfilgrastimum #**

empegfilgrastim

[1-(*N*-{4-[ω-methoxypoly(oxyethylene)]butyl}-*L*-methionine)]human granulocyte colony-stimulating factor (pluripoietin)

empegfilgrastim

[1-(*N*-{4-[ω-méthoxypoly(oxyéthylène)]butyl}-*L*-méthionine)]facteur de stimulation des colonies de granulocytes humain (pluripoéétine)

empegfilgrastim


[1-(*N*-{4-[ω-metoxipoli(oxietileno)]butil}-*L*-metionina)]factor humano de estimulación de las colonias de granulocitos (pluripoyetina)

MTPLGPASSL PQSFLKCLE QVRKIQGDGA ALQEKLCATY KLCHPEELVL 50
 LGHSLGIPWA PLSSCPSQAL QLAGCLSOLH SGLFLYQGLL QALEGISPEL 100
 GPTLDTLQLD VADFATTIQ QMEELGMAPA LQPTQGAMPA FASAFQRRAG 150
 GVLVASHLQS FLEVSRYVLR HLAQP 175

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 37-43 65-75

Modified residue / Résidu modifié / Resto modificado

M
 I
 PEG-Met

**enobosarmum**


enobosarm

(2*S*)-3-(4-cyanophenoxy)-*N*-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide

énobosarm

(2*S*)-3-(4-cyanophénoxy)-*N*-[4-cyano-3-(trifluorométhy)phényl]-2-hydroxy-2-méthylpropanamide

enobosarm


(2*S*)-3-(4-cianofenoxi)-*N*-[4-ciano-3-(trifluorometil)fenil]-2-hidroxi-2-metilpropanamidaC₁₉H₁₄F₃N₃O₃

enoticumabum # enoticumab	immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> DLL4 (delta-like 4)], <i>Homo sapiens</i> monoclonal antibody; gamma1 heavy chain (1-452) [<i>Homo sapiens</i> VH (IGHV3-33*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*01 CHS K2>del (124-452)], (226-214')-disulfide with kappa light chain (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (232-232':235-235')-bisdisulfide dimer
énoticumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> DLL4 (delta-like 4)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-452) [<i>Homo sapiens</i> VH (IGHV3-33*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*01 CHS K2>del (124-452)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (232-232':235-235')-bisdisulfure
enoticumab	inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> DLL4 (delta-like 4)], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena pesada gamma1 (1-452) [<i>Homo sapiens</i> VH (IGHV3-33*01 (90.80%) -(IGHD)-IGHJ5*02) [8.8.16] (1-123) -IGHG1*01 CHS K2>del (124-452)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (232-232':235-235')-bisdisulfuro
	Heavy chain / Chaîne lourde / Cadena pesada QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVSF 50 LWYDGTNKNY VESVKGFRFI SRDNSKNMLY LEMNSLRAED TAVVYCARDH 100 DFRSGYEGWF DPWQGTLVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150 LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200 TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSPVFLFP 250 KPKKDTLMIS RTPVETCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPRRE 300 QYNSTYRVVS VLTVLRHQLDL NGKEYCKVK NKALPAPIEK TISKAKGQPR 350 EPQVYTLPPS RDELTKNQS LTCLVKGFYP SDIAVEWESN GQPPENNYKTT 400 FPVLDSGGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSL 450 EG 452
	Light chain / Chaîne légère / Cadena ligera EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKQ GQAPRLLIYD 50 ASNRAIGIPA RFGSGSGSDT FTLTISSELP EDFAVYYCQH RSNWPPFTFG 100 GTRKVEIKRTV AAPSVEIFPP SDEQLKSGTA SVVCLLNFFY PREAKVQWQV 150 DNALQSGNSQ ESVTEQDSKD STYSLSSLT LSKADYEKHK VYACEVTHQG 200 LSSPEVTKSFN RGEC 214
	Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 22-96 150-206 267-327 373-431 22"-96" 150"-206" 267"-327" 373"-431" Intra-L 23'-88' 134'-194' 23'''-88''' 134'''-194''' Inter-H-L 226-214' 226"-214" Inter-H-H 232-232" 235-235"
	N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 303, 303"
ensereptidum ensereptide	acetyl(human lactotransferrin-(15-39)-peptidamide)
enséreptide	acétyl(lactotransferrine humaine-(15-39)-peptidamide)
ensereptida	acetil(lactotransferrina humana-(15-39)-peptidamida)

EATKCFQWQR NMRKVRGPPV SCIKR 25

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
5 - 22


Modified residues / Résidus modifiés / Restos modificados

**enzalutamidum**
enzalutamide4-{3-[4-cyano-3-(trifluoromethyl)phenyl]-5,5-dimethyl-4-oxo-2-sulfanylideneimidazolidin-1-yl}-2-fluoro-*N*-methylbenzamide

enzalutamide

4-{3-[4-cyano-3-(trifluorométhyl)phényl]-5,5-diméthyl-4-oxo-2-sulfanylidèneimidazolidin-1-yl}-2-fluoro-*N*-méthylbenzamide


enzalutamida

4-{3-[4-ciano-3-(trifluorometil)fenil]-5,5-dimetil-4-oxo-2-sulfanilidenoimidazolidin-1-il}-2-fluoro-*N*-metilbenzamidaC₂₁H₁₆F₄N₄O₂S**ertugliflozinum**
ertugliflozin(1*S*,2*S*,3*S*,4*R*,5*S*)-5-{4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl}-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol

ertugliflozine

(1*S*,2*S*,3*S*,4*R*,5*S*)-5-{4-chloro-3-[(4-éthoxyphényl)méthyl]phényl}-1-(hydroxyméthyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol

ertugliflozina

(1*S*,2*S*,3*S*,4*R*,5*S*)-5-{4-cloro-3-[(4-etoxifenil)metil]fenil}-1-(hidroximetil)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triolC₂₂H₂₅ClO₇

etirinotecanum pegolum

etirinotecan pegol


tetrakis{(4*S*)-9-([1,4'-bipiperidine]-1'-carbonyloxy)-4,11-diethyl-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-yl} *N,N',N'',N'''*-{methanetetrayltetrakis[methylenepoly(oxyethylene)oxy(1-oxoethylene)]}tetraglycinate

étirinotécan pégol

N,N',N'',N'''-{méthanetetrayltétrakis[méthylènepoly(oxyéthylène)oxy(1-oxoéthylène)]}tétraglycinate de tétrakis{(4*S*)-9-([1,4'-bipéridine]-1'-carbonyloxy)-4,11-diéthyl-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-4-yle}

etirinotecán pegol

N,N',N'',N'''-{metanotetrailtetrakis[metilènepoli(oxietilene)oxi(1-oxoetileno)]}tetraglicinato de tetrakis{(4*S*)-9-([1,4'-bipiperidina]-1'-carboniloxi)-4,11-dietil-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-ilo}

 $C_{153}H_{176}N_{20}O_{36} [C_8H_{16}O_4]_n$
**evogliptinum**

evogliptin


(3*R*)-4-[(3*R*)-3-amino-4-(2,4,5-trifluorophenyl)butanoyl]-3-(*tert*-butoxymethyl)piperazin-2-one

évogliptine

(3*R*)-4-[(3*R*)-3-amino-4-(2,4,5-trifluorophényl)butanoyl]-3-(*tert*-butoxyméthyl)pipérazin-2-one

evogliptina

(3*R*)-4-[(3*R*)-3-amino-4-(2,4,5-trifluorofenil)butanoil]-3-(*terc*-butoximetil)piperazin-2-ona

 $C_{19}H_{26}F_3N_3O_3$
**fasiglifamum**


fasiglifam

[(3*S*)-6-((2',6'-dimethyl-4'-[3-(methanesulfonyl)propoxy]-[1,1'-biphenyl]-3-yl))methoxy]-2,3-dihydro-1-benzofuran-3-yl]acetic acid

fasiglifam acide [(3S)-6-((2',6'-diméthyl-4'-[3-(méthanesulfonyl)propoxy]-[1,1'-biphényl]-3-yl)méthoxy)-2,3-dihydro-1-benzofuran-3-yl]acétique

fasiglifam ácido [(3S)-6-((2',6'-dimetil-4'-[3-(metanosulfonyl)propoxi]-[1,1'-bifenil]-3-il))metoxi)-2,3-dihidro-1-benzofuran-3-il]acético

C₂₉H₃₂O₇S



fasinumabum #
fasinumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF)], *Homo sapiens* monoclonal antibody;
gamma4 heavy chain (1-446) [*Homo sapiens* VH (IGHV1-24*01 (95.90%) -(IGHD)-IGHJ5*01 [8.8.12] (1-119) -IGHG4*01 hinge S10>P (227) (120-446)], (133-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (90.50%) -IGKJ1*01 [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (225-225'':228-228'')-bisdisulfide dimer

fasinumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* NGF (facteur de croissance du nerf, facteur de croissance du nerf polypeptide bêta, NGFB, bêta-NGF)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma4 (1-446) [*Homo sapiens* VH (IGHV1-24*01 (95.90%) -(IGHD)-IGHJ5*01 [8.8.12] (1-119) -IGHG4*01 charnière S10>P (227) (120-446)], (133-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (90.50%) -IGKJ1*01 [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (225-225'':228-228'')-bisdisulfure

fasinumab

immunoglobulina G4-kappa, anti-[NGF de *Homo sapiens* (factor de crecimiento neuronal, factor de crecimiento neuronal polipeptido beta, NGFB, beta-NGF)], anticuerpo monoclonal de *Homo sapiens*;
cadena pesada gamma4 (1-446) [*Homo sapiens* VH (IGHV1-24*01 (95.90%) -(IGHD)-IGHJ5*01 [8.8.12] (1-119) -IGHG4*01 bisagra S10>P (227) (120-446)], (133-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV1-17*01 (90.50%) -IGKJ1*01 [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (225-225'':228-228'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE	VKKPGASVKV	SCKVSQFTLT	ELSIHWVRQA	PGKGLEWMMG	50
FDPEDEGTIY	AQKFKQGRVTM	TEDTSTDTAY	MELTSLRSED	TAVYYCSTIF	100
GVVTFNFDNWG	QGTLVTVSSA	STKGPSVFPFL	APCSRSTSES	TAALGCLVKD	150
YFPPEPVTWSW	NSGALTSGVH	TFFPAVLQSSG	LYSLSSVTV	PSSSLGKTGY	200
TCNVDHRPSN	TKVDRRVESK	YGPPCPPCPA	PEFLGGPSVF	LFPPKPKDTL	250
MISRTPEVTC	VVVDVSDQEDP	EVQFNWYVDG	VEVHNAKTRP	REEQFNSTYR	300
VVSVLTVLHQ	DWLNKGEYKC	KVSNKGLPSS	IEKTISKARG	QPREPQVYTL	350
PPSQEEMTRN	QVSLTCLVKG	FYPSDIAVEW	ESNGQPENNY	KTTTTPVLDSD	400
GSFFLYSRLT	VDKSRWQEGN	VFSCSVMEHA	LHNHYTQKSL	SLSLGK	446

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS	LSASAGDRV	ITCRASQAIR	NLQWYQQK	GKAPKRLIYA	50
AFNLQSGVPS	RFSGSGSGTE	FTLTISLQ	EDLASYYCQ	YNRYPTWTFGQ	100
GTKVEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNEY	PREAKVQWKV	150
DNALQSGNSQ	ESVTEQDSKD	STYLSLSTLT	LSKADYEKHK	VYACEVTHQG	200
LSSPVTKSFN	RGEC				214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 146-202 260-320 366-424
22''-96'' 146''-202'' 260''-320'' 366''-424''

Intra-L 23'-88'' 134'-194''
23'''-88''' 134'''-194'''

Inter-H-L 133-214' 133''-214''

Inter-H-H 225-225'' 228-228''

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
H CH2 N84.4:
296, 296'

firtecanum pegolum

firtecan pegol


tetrakis[(4*S*)-4,11-diethyl-9-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-yl] *N,N',N'',N'''*-(oxybis{(propane-3,1,2-triyl)bis[poly(oxyethylene)oxy(1-oxoethylene)]})tetraglycinate

firtécan pégol

N,N',N'',N'''-(oxybis{(propane-3,1,2-triyl)bis[poly(oxyéthylène)oxy(1-oxoéthylène)]})tétraglycinate de tétrakis[(4*S*)-4,11-diéthyl-9-hydroxy-3,14-dioxo-3,4,12,14-tétrahydro-1*H*-pyrano[3',4':6,7]indolizino[1,2-*b*]quinoléin-4-yle]

firtécán pegol

N,N',N'',N'''-(oxibis{(propano-3,1,2-triil)bis[poli(oxietileno)oxi(1-oxoetileno)]})tetraglicinato de tetrakis[(4*S*)-4,11-diétil-9-hidroxi-3,14-dioxo-3,4,12,14-tetrahidro-1*H*-pirano[3',4':6,7]indolizino[1,2-*b*]quinolin-4-ilo]

 $C_{110}H_{106}N_{12}O_{33} (C_2H_4O)_n$
**fluralanerum**

fluralaner


4-[5-(3,5-dichlorophenyl)-5-(trifluoromethyl)-4,5-dihydro-1,2-oxazol-3-yl]-2-methyl-*N*-{2-oxo-2-[(2,2,2-trifluoroethyl)amino]ethyl}benzamide

fluralaner

4-[(5*RS*)-5-(3,5-dichlorophényl)-5-(trifluorométhyl)-4,5-dihydro-1,2-isoxazol-3-yl]-2-méthyl-*N*-{2-oxo-2-[(2,2,2-trifluoroéthyl)amino]éthyl}benzamide

fluralaner

4-[5-(3,5-diclorofenil)-5-(trifluorometil)-4,5-dihidro-1,2-oxazol-3-il]-2-metil-*N*-{2-oxo-2-[(2,2,2-trifluoroetil)amino]etil}benzamida

 $C_{22}H_{17}Cl_2F_6N_3O_3$


and enantiomer
et énantiomère
y enantiómero

futuximabum #

futuximab

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, ERBB1, HER1) domain III], chimeric monoclonal antibody;
 gamma1 heavy chain (1-452) [*Mus musculus* VH (IGHV1S5*01 - (IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 CHS K2>del (124-452)], (226-214')-disulfide with kappa light chain (1'-214') [*Mus musculus* V-KAPPA (IGKV10-96*01 -IGKJ1*02) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; (232-232":235-235")-bisdisulfide dimer

futuximab

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique ERBB1, HER1) domaine III], anticorps monoclonal chimérique;
 chaîne lourde gamma1 (1-452) [*Mus musculus* VH (IGHV1S5*01 - (IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 CHS K2>del (124-452)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV10-96*01 -IGKJ1*02) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dimère (232-232":235-235")-bisdisulfure

futuximab

immunoglobulina G1-kappa, anti-[EGFR de *Homo sapiens* (receptor del factor de crecimiento epidérmico ERBB1, HER1) dominio III], anticuerpo monoclonal quimérico;
 cadena pesada gamma1 (1-452) [*Mus musculus* VH (IGHV1S5*01 - (IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 CHS K2>del (124-452)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [*Mus musculus* V-KAPPA (IGKV10-96*01 -IGKJ1*02) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLQQPGSE LVRPGASVKL SCKASGYTFT SYWMHWVKQR FGQGLEWIGN 50
IYPGSRSTNY DEKFKSKATL TVDTSSSTAY MQLSSLTSED SAVYYCTRNG 100
DYVSSGSDAM DYWGQGTSTV VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKR VEPKSCDKH TCPCPAPEL LGGFSPVLEFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDEPKV FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVVS VLTVLHQDWL NGKEYCKKVS NKALPAPIEK TISKARGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFPY SDIAVEMESN GPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTKSLSLS 450
PG 452
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQTTSS LSASLGDRVT ISCRTSQDIG NYLWYQQKPK DGTVKKLIYY 50
TSRLHSGVPS RFGSGSGSDT FSLTINNVEQ EDVATYFCQH YNTVPTTFGG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22-96 150-206 267-327 373-431
22"-96" 150"-206" 267"-327" 373"-431"
Intra-L 23'-88" 134'-194"
23"'-88"' 134"'-194"'
Inter-H-L 226-214' 226"-214'"
Inter-H-H 232-232" 235-235"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación


H CH2 84.4:
303, 303"

giminabantum

giminabant

3-chloro-4-((2R)-2-(4-chlorophenyl)-
4-[(1R)-1-(4-cyanophenyl)ethyl]piperazin-1-yl)benzonitrile

giminabant	3-chloro-4-((2 <i>R</i>)-2-(4-chlorophényl)-4-[(1 <i>R</i>)-1-(4-cyanophényl)éthyl]pipérazin-1-yl)benzotrile
giminabant	3-cloro-4-((2 <i>R</i>)-2-(4-clorofenil)-4-[(1 <i>R</i>)-1-(4-cianofenil)etil]pipérazin-1-il)benzotrilo

C₂₆H₂₂Cl₂N₄

golvatinibum
golvatinib


N-[2-fluoro-4-((2-[4-(4-méthylpipérazin-1-yl)]pipéridine-1-carboxamido)pyridin-4-yl)oxy)phényl]-*N'*-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

golvatinib

N-[2-fluoro-4-((2-[4-(4-méthylpipérazin-1-yl)]pipéridine-1-carboxamido)pyridin-4-yl)oxy)phényl]-*N'*-(4-fluorophényl)cyclopropane-1,1-dicarboxamide

golvatinib

N-[2-fluoro-4-((2-[4-(4-méthylpipérazin-1-il)]pipéridina-1-carboxamido)piridin-4-il)oxi)fenil]-*N'*-(4-fluorofenil)ciclopropano-1,1-dicarboxamida

C₃₃H₃₇F₂N₇O₄

ibrutinibum
ibrutinib


1-((3*R*)-3-[4-amino-3-(4-phénoxyphényl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl]pipéridin-1-yl)prop-2-en-1-one

ibrutinib

1-((3*R*)-3-[4-amino-3-(4-phénoxyphényl)-1*H*-pyrazolo[3,4-*d*]pyrimidin-1-yl]pipéridin-1-yl)prop-2-én-1-one

ibrutinib

1-((3*R*)-3-[4-amino-3-(4-fenoxifenil)-1*H*-pirazolo[3,4-*d*]pirimidin-1-il]pipéridin-1-il)prop-2-en-1-ona

C₂₅H₂₄N₆O₂

idelalisibum

idelalisib


5-fluoro-3-phenyl-2-[(1S)-1-[(7H-purin-6-yl)amino]propyl]quinazolin-4(3H)-one

idélalisib

5-fluoro-3-phényl-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4(3H)-one

idelalisib

5-fluoro-3-fenil-2-[(1S)-1-(7H-purin-6-ilamino)propil]quinazolin-4(3H)-ona

C₂₂H₁₈FN₇O**imgatuzumabum #**

imgatuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, ERBB1, HER1)], humanized monoclonal antibody;

gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens*IGHV1-46*01 (83.70%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -*Homo sapiens*IGHG1*01 CHS K2>del (121-449)], (223-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens*IGKV1-17*01 (90.50%) -IGKJ2*01) [6.3.8] (1'-106') -*Homo sapiens*IGKC*01 (107'-213'')]; (229-229'':232-232'')-bisdisulfide dimer

imgatuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (récepteur du facteur de croissance épidermique ERBB1, HER1)], anticorps monoclonal humanisé;

chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens*IGHV1-46*01 (83.70%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -*Homo sapiens*IGHG1*01 CHS K2>del (121-449)], (223-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens*IGKV1-17*01 (90.50%) -IGKJ2*01) [6.3.8] (1'-106') -*Homo sapiens*IGKC*01 (107'-213'')]; dimère (229-229'':232-232'')-bisdisulfure

imgatuzumab

inmunoglobulina G1-kappa, anti-[EGFR de *Homo sapiens* (receptor del factor de crecimiento epidérmico ERBB1, HER1)], anticuerpo monoclonal humanizado;

cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens*IGHV1-46*01 (83.70%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -*Homo sapiens*IGHG1*01 CHS K2>del (121-449)], (223-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens*IGKV1-17*01 (90.50%) -IGKJ2*01) [6.3.8] (1'-106') -*Homo sapiens*IGKC*01 (107'-213'')]; dímero (229-229'':232-232'')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 VQQLVQSGAE VKKPGSSVKV SCKASGFTFT DYKIHWRQA PGQGLEWMGY 50
 FNPNSGYSTY AQKFQGRVTI TADKSTSTAY MELSSLRSED TAVYYCARLS 100
 PGGYVMDAW GQGTITVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
 DYFPEPVTVS WNSGALTSKV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
 YICNVNHKPS NTKVDKVEP KSCDKHTHTCP PCPAPPELLGG PSVFLFPPPK 250
 KDTLMISRTPEVTCVVDVSD HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
 STYRVVSVLT VLNQDNLNGK EYKCKVSNKA LPAPIEKTI S KAKGQPREPQ 350
 VYTLPPSRDE LTKNQVSLTLC LVKGFYPSDI AVEWESNGQP ENNYKTTTPPV 400
 LDDSDGSEFFLY SKLTVDKSRW QQGNVFCSCV MHEALHNHYT QKSLSLSPG 449

Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS LSASVGRVITITCRASQGIN NYLNWYQQKPK GKAPKRLIYN 50
 TNNLQGTGVPF RFSGSGSGTE FTLTISSLQP EDFATYYCLQ HNSFPTFGQG 100
 TKLEIKRTVA APSVFIFFPPS DEQLKSGTAS VVCLLNRFYF REAKVQWKVD 150
 NALQSGNSQEQ SVTEQDSKDS TYSLSTLTLL SKADYEKHKV YACEVTHQGL 200
 SSPVTKSFNR GEC 213

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H 22-96 147-203 264-324 370-428
 22"-96" 147"-203" 264"-324" 370"-428"
 Intra-L 23"-88" 133"-193"
 23"-88" 133"-193"
 Inter-H-L 223-213' 223"-213"
 Inter-H-H 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 300, 300"

insulinum peglisprum

insulin peglispro


macrogol 20000 pegylated insulin lispro:
 [28^B-(6-N-[[ω-methoxypoly(oxyethylene)]carbonyl]-L-lysine),
 29^B-L-proline]human insulin

insuline péglispro

insuline lispro péglée avec du macrogol 20000:
 [28^B-(6-N-[[ω-méthoxypoly(oxyéthylène)]carbonyl]-L-lysine),
 29^B-L-proline]insuline humaine

insulina peglispro

insulina lispro pegilada con macrogol 20000:
 [28^B-(6-N-[[ω-metoxipoli(oxietileno)]carbonil]-L-lisina),
 29^B-L-prolina]insulina humana

**lampalizumabum #**

lampalizumab

immunoglobulin Fab G1-kappa, anti-[*Homo sapiens* CFD (complement factor D)], humanized monoclonal antibody; VH -(CH1-hinge) gamma1 heavy chain (1-223) [humanized VH (*Homo sapiens* IGHV7-4-1*02 (88.80%) -(IGHD)-IGHJ5*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*01 CH1 (116-213), hinge 1-10 (214-223)], (218-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-33*01 (77.90%) -IGKJ2*01 L124>V (104) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]

lampalizumab

immunoglobuline Fab G1-kappa, anti-[*Homo sapiens* CFD (facteur D du complément)], anticorps monoclonal humanisé; chaîne lourde VH -(CH1-charnière) gamma1 (1-223) [VH humanisé (*Homo sapiens* IGHV7-4-1*02 (88.80%) -(IGHD)-IGHJ5*01) [8.8.8] (1-115) -*Homo sapiens* IGHG1*01 CH1 (116-213), charnière 1-10 (214-223)], (218-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-33*01 (77.90%) -IGKJ2*01 L124>V (104) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]

lampalizumab

inmunoglobulina Fab G1-kappa, anti-[CFD (factor D del complemento) de *Homo sapiens*], anticuerpo monoclonal humanizado;
cadena pesada VH -(CH1-bisagra) gamma1 (1-223) [VH humanizado (*Homo sapiens*IGHV7-4*1*02 (88.80%) -(IGHD)-IGHJ5*01) [8.8.8] (1-115) -*Homo sapiens*IGHG1*01 CH1 (116-213), bisagra 1-10 (214-223)], (218-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV1-33*01 (77.90%) -IGKJ2*01 L124>V (104) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01 (108'-214')]

Heavy chain / Chaîne lourde / Cadena pesada
EVQLVQSGPE LKKPGASVKV SCKASGYFTF NYGMNWRQA PGQGLEWMGW 50
INTYTGETTY ADDFKGRFVF SLDTSVSTAY LQISSLKAED TAVVYCEREG 100
GVNHWGQGTI VIVSSASTKG PSVFPLAPSS KSTSGGTAAL GCLVKDYFPE 150
PVTVSWNSGA LTVGVHTFPA VLQSSGLYSI SSVVTVPSSS LGTQTYICNV 200
NHKPSNTKVD KKVEPKSCDK THT 223

Light chain / Chaîne légère / Cadena ligera
DIQVTSQSPSS LSASVGRVIT ITCITSTDDI DDMNRYQQKP GKVPKLLISG 50
GNTLRFGVPS RFGSGSGSDT FTLTISLQF EDVATYYCLQ SDSLPYTFGQ 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNFFY FREAKVQWKV 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
Intra-H 22-96 142-198
Intra-L 23'-88' 134'-194'
Inter-H-L 218-214'

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
None

latanoprostenum bunodum

latanoprostene bunod


4-(nitrooxy)butyl (5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phenylpentyl]cyclopentyl)hept-5-enoate

latanoprostène bunod

(5Z)-7-((1R,2R,3R,5S)-3,5-dihydroxy-2-[(3R)-3-hydroxy-5-phénylpentyl]cyclopentyl)hept-5-énoate de 4-(nitrooxy)butyle

latanoprosteno bunod

(5Z)-7-((1R,2R,3R,5S)-3,5-dihidroxi-2-[(3R)-3-hidroxi-5-fenilpentil]ciclopentil)hept-5-enoato de 4-(nitrooxi)butilo

C₂₇H₄₁NO₈

latromotidum

latromotide


human kinesin-like protein KIF20A-(66-75)-peptide

latromotide

membre 20A des protéines de la famille des kinésines humaines-(66-75)-peptide

latromotida

miembro 20A de las proteínas de la familia de las kinesinas humanas-(66-75)-péptido

	$C_{60}H_{105}N_{17}O_{12}$
	H-Lys—Val—Tyr—Leu—Arg—Val—Arg—Pro—Leu—Leu—OH
lifitegrastum lifitegrast	(2S)-2-{2-[(1-benzofuran-6-yl)carbonyl]}-5,7-dichloro-1,2,3,4-tetrahydroisoquinolin-6-carboxamido}-3-[3-(methanesulfonyl)phenyl]propanoic acid
lifitégrast	acide (2S)-2-{2-[(1-benzofuran-6-yl)carbonyl]}-5,7-dichloro-1,2,3,4-tétrahydroisoquinoléin-6-carboxamido}-3-[3-(méthanesulfonyl)phényl]propanoïque
lifitegrast	ácido (2S)-2-{2-[(1-benzofuran-6-il)carbonil]}-5,7-dicloro-1,2,3,4-tetrahidroisoquinolin-6-carboxamido}-3-[3-(metanosulfonyl)fenil]propanoico
	$C_{29}H_{24}Cl_2N_2O_7S$
	
ligelizumabum # ligelizumab	immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> IGHE (immunoglobulin constant epsilon (IGHE) region of the heavy chain of IgE) CH3 1.3-9 (12 AA), 108-121 (12 AA) epitope], humanized monoclonal antibody; gamma1 heavy chain (1-453) [humanized VH (<i>Homo sapiens</i> IGHV1-69*11 (80.60%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) - <i>Homo sapiens</i> IGHG1*01 (124-453)], (226-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV3-15*01 (86.30%) -IGKJ4*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01 (108'-214')]; (232-232":235-235")-bisdisulfide dimer
ligélizumab	immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> IGHE (région constante epsilon (IGHE) de la chaîne lourde des immunoglobulines IgE) épitope CH3 1.3-9 (12 AA), 108-121 (12 AA)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-453) [VH humanisé (<i>Homo sapiens</i> IGHV1-69*11 (80.60%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) - <i>Homo sapiens</i> IGHG1*01 (124-453)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV3-15*01 (86.30%) -IGKJ4*01) [6.3.9] (1'-107') - <i>Homo sapiens</i> IGKC*01 (108'-214')]; dimère (232-232":235-235")-bisdisulfure

ligelizumab

immunoglobulina G1-kappa, anti-[IGHE de *Homo sapiens* (región constante epsilon (IGHE) de la cadena pesada de las inmunoglobulinas IgE) epítipo CH3 1.3-9 (12 AA), 108-121 (12 AA)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-453) [VH humanizada (*Homo sapiens* IGHV1-69*11 (80.60%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01 (124-453)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV3-15*01 (86.30%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VMKPGSSVKV SCKASGYTFS WYWLEWVRQA PGHGLEWMGE 50
IDPGTFTTNY NEKFKARVTF TADTSTSTAY MELSSLRSED TAVYYCARFS 100
HFGSGSNYDYF DYWGQGTLVV VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVFSSSLG 200
TQTYICNVNH KPSNTKVDK KVEPKSCDKTH TCPCPAPEL LGGSPVFLPF 250
PKPKDTLMIS RTPEVTCVVV DVSHEDEPKV FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS RDELTKNQVS LTCILVKGFFYP SDIAVEWESN GQPENNYKTT 400
PFVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSL 450
PGK 453

Light chain / Chaîne légère / Cadena ligera

EIVMTQSPAT LSVSPGERAT LSCRASQSIG TNIHWYQQKP GQAPRLLIYY 50
ASESISGIPA RFGSGSGSTE FTLTISSLQS EDFAVYICQQ SWSWFTTFGG 100
GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWQV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYERHK VYACEVTHQG 200
LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 150-206 267-327 373-431
22"-96" 150"-206" 267"-327" 373"-431"
Intra-L 23'-88" 134'-194"
23"'-88"' 134"'-194"
Inter-H-L 226-214' 226"-214"
Inter-H-H 232-232" 235-235"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
303, 303"

lirilumabum #
lirilumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* KIR2D subgroup (killer cell immunoglobulin-like receptors from KIR2D subgroup including KIR2DL1 (nkat1, CD158A), KIR2DL2 (nkat6, CD158B1), KIR2DL3 (nkat2, CD158B2), KIR2DS1 (CD158H) and KIR2DS2 (nkat5, CD158J)], *Homo sapiens* monoclonal antibody; gamma4 heavy chain (1-450) [*Homo sapiens* VH (IGHV1-69*01 (95.90%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG4*01 hinge S10>P (231) (124-450)], (137-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (229-229":232-232")-bisdisulfide dimer

lirilumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* KIR2D sous-groupe (récepteurs des cellules tueuses du sous-groupe KIR2D appartenant à la superfamille des immunoglobulines et incluant KIR2DL1 (nkat1, CD158A), KIR2DL2 (nkat6, CD158B1), KIR2DL3 (nkat2, CD158B2), KIR2DS1 (CD158H) et KIR2DS2 (nkat5, CD158J)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma4 (1-450) [*Homo sapiens* VH (IGHV1-69*01 (95.90%) -(IGHD)-IGHJ6*01) [8.8.16] (1-123) -IGHG4*01 charnière S10>P (231) (124-450)], (137-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ2*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (229-229":232-232")-bisdisulfure

lirilumab
 inmunoglobulina G4-kappa, anti-[subgrupo KIR2D de *Homo sapiens* (receptores de células asesinas del subgrupo KIR2D perteneciente a la superfamilia de las inmunoglobulinas y que incluye KIR2DL1 (nkat1, CD158A), KIR2DL2 (nkat6, CD158B1), KIR2DL3 (nkat2, CD158B2), KIR2DS1 (CD158H) et KIR2DS2 (nkat5, CD158J)], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma4 (1-450) [*Homo sapiens* VH (IGHV1-69*01 (95.90%) -(IGHD)-IGHJ6*01 [8.8.16] (1-123) -IGHG4*01 bisagra S10>P (231) (124-450)], (137-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ2*01 [6.3.9] (1'-107') -IGKC*01 (108'-214')]]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLVQSGAE VKKPGSSVKV SCKASGGTFS FYAISWVRQA PGQGLEWMGG 50
 FIPIFGAANY AqKFQGRVTI TADESTSTAY MELSSLRSD TAVVYCARIP 100
 SGSYYDYDM DVWGQGTIVT VSSASTKGPS VFPLAPCSRS TSESTAALGC 150
 LVKDYFFPEPV TVSNWNGALT SGVHTFPVAVL QSSGLYSLSS VVTVPSSSLG 200
 TKTYTCNVDH KPSNTKVDKR VESKYGPFCP PCPAPPEFLGG PSVFLFPFKP 250
 KDTLMSRTP EVTCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN 300
 STYRVVSVLT VLNQDNLNGK EYKCKVSNKG LPSSIIEKTIK KAKGQPREPQ 350
 VYTLPPSQEE MTRNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPPV 400
 LDDSDGFFFLY SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSLGK 450

Light chain / Chaîne légère / Cadena ligera
 EIVLTQSPVT LSLSPGERAT LSCRASQSVS SYLAWYQQKQ GPAPRLLIYD 50
 ASNRTATGIPA RFGSGSGSDT FTLTISSELP EDFAVYYCQQ RSNWMTYFGQ 100
 GTKLEIKRTV AAFPSVFIIPP SDEQLKSGTA SVVCLLNIFY PREAKVQWQV 150
 DNALQSGNSQ ESVTEQDSK STYSLSSLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGECL 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H 22-96 150-206 264-324 370-428
 22"-96" 150"-206" 264"-324" 370"-428"
 Intra-L 23'-88' 134'-194'
 23'''-88''' 134'''-194'''
 Inter-H-L 137-214' 137"-214"
 Inter-H-H 229-229" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 300, 300'

lomibuvirum
 lomibuvir

5-(3,3-dimethylbut-1-yn-1-yl)-3-((*trans*-4-hydroxycyclohexyl)((*trans*-4-methylcyclohexyl)carbonyl)amino)thiophene-2-carboxylic acid


lomibuvir

acide 5-(3,3-diméthylbut-1-yn-1-yl)-3-((*trans*-4-hydroxycyclohexyl)((*trans*-4-méthylcyclohexyl)carbonyl)amino)thiophène-2-carboxylique

lomibuvir


ácido 5-(3,3-dimetilbut-1-in-1-il)-3-((*trans*-4-hidroxiciclohexil)((*trans*-4-metilciclohexil)carbonil)amino)tiofeno-2-carboxílico

C₂₅H₃₅NO₄S




lucitanibum

lucitanib	6-({7-[(1-aminocyclopropyl)methoxy]-6-methoxyquinolin-4-yl}oxy)- <i>N</i> -methylnaphthalene-1-carboxamide
lucitanib	6-({7-[(1-aminocyclopropyl)méthoxy]-6-méthoxyquinoléin-4-yl}oxy)- <i>N</i> -méthyl-naphthalène-1-carboxamide
lucitanib	6-({7-[(1-aminociclopropil)metoxi]-6-metoxiquinolin-4-il}oxi)- <i>N</i> -metilnaftaleno-1-carboxamida

C₂₆H₂₅N₃O₄**momelotinibum**

momelotinib	<i>N</i> -(cyanomethyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide
momélotinib	<i>N</i> -(cyanométhyl)-4-{2-[4-(morpholin-4-yl)anilino]pyrimidin-4-yl}benzamide
momelotinib	<i>N</i> -(cianometil)-4-{2-[4-(morfolin-4-il)anilino]pirimidin-4-il}benzamida

C₂₃H₂₂N₆O₂**nivolumabum #**

nivolumab	immunoglobulin G4-kappa, anti-[<i>Homo sapiens</i> PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], <i>Homo sapiens</i> monoclonal antibody; gamma1 heavy chain (1-440) [<i>Homo sapiens</i> VH (IGHV3-33*01 (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 hinge S10>P (221) (114-440)], (127-214')-disulfide with kappa light chain (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; (219-219':222-222'')-bisdisulfide dimer
nivolumab	immunoglobuline G4-kappa, anti-[<i>Homo sapiens</i> PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-440) [<i>Homo sapiens</i> VH (IGHV3-33*01 (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 charnière S10>P (221) (114-440)], (127-214')-disulfure avec la chaîne légère kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dimère (219-219'':222-222'')-bisdisulfure

nivolumab	<p>inmunoglobulina G4-kappa, anti-[PDCD1 de <i>Homo sapiens</i> (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal de <i>Homo sapiens</i>;</p> <p>cadena pesada gamma1 (1-440) [<i>Homo sapiens</i> VH (IGHV3-33*01 (91.80%) -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -IGHG4*01 bisagra S10>P (221) (114-440)], (127-214')-disulfuro con la cadena ligera kappa (1'-214') [<i>Homo sapiens</i> V-KAPPA (IGKV3-11*01 (98.90%) -IGKJ1*01) [6.3.9] (1'-107') -IGKC*01 (108'-214')]; dímero (219-219":222-222")-bisdisulfuro</p> <p>Heavy chain / Chaîne lourde / Cadena pesada</p> <pre> QVQLVESGGG VVQPGRSLRL DCKASGITFS NSGMHWVRQA PGKGLEWVAV 50 IWYDQSKRYI ADSVKGRFTI SRDNSKNTLF LQMNSLRAED TAVVYCATND 100 DYWGQGTLLVT VSSASTKGPS VFPLAPCSRS TSESTAALGC LVKDYFPEPV 150 TVSWNSGALT SGVHTFFPAVL QSSGLYLSLS VVTVFPSSSLG KTTYTCNVNH 200 KPSNTKVDRK VESKYGPPCP PCPAPEFLGG PSVFLFPPKP KDTLMSRTP 250 EVTCCVVVDVS QEDPEVQFNW YVDGVEVHNA KTKPREEQFN STYRVVSVLT 300 VLHQDNLNGK EYKCKVSNKG LPSSIEKTIS KAKGQPREPQ VYTLFPSQEE 350 MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTTPV LDSDGSFFLY 400 SRLTVDKSRW QEGNVFSCSV MHEALHNHYT QKSLSLSLGK 440 </pre> <p>Light chain / Chaîne légère / Cadena ligera</p> <pre> EIVLTQSPAT LSLSPGERAT LSCRASQSVS SYLAWYQQKQ GPAPRLLIYD 50 ASNRAATGIPA RFGSGSGSDT FTLTISSELP EDFAVYYCQQ SSNWPRTFGQ 100 GTRKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNPFY PREAKVQWV 150 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200 LSSFVTKSFN RGECE 214 </pre> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <pre> Intra-H 22-96 140-196 254-314 360-418 22"-96" 140"-196" 254"-314" 360"-418" Intra-L 23'-88' 134'-194' 23"'-88"" 134"'-194"" Inter-H-L 127-214' 127"-214" Inter-H-H 219-219" 222-222" </pre> <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación</p> <pre> H CH2 84.4: 290, 290" </pre>
ocaratumzumabum # ocaratumzumab	<p>immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> MS4A1 (membrane-spanning 4-domains subfamily A member 1, CD20)], humanized monoclonal antibody;</p> <p>gamma1 heavy chain (1-450) [humanized VH (<i>Homo sapiens</i> IGHV5-51*01 (83.70%) -(IGHD)-IGHJ2*01) R120>K (113), L123>T (116) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG1*01 CH2 P11>I (251), A124>Q (343), CHS K2>del (122-450)], (224-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV3-20*01 (85.40%) -IGKJ2*01) [5.3.9] (1'-106') -<i>Homo sapiens</i> IGKC*01 (107'-213')]; (230-230":233-233")-bisdisulfide dimer</p>
ocaratumzumab	<p>immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> MS4A1 (membre 1 de la sous-famille A à 4 domaines transmembranaires, CD20)], anticorps monoclonal humanisé;</p> <p>chaîne lourde gamma1 (1-450) [VH humanisé (<i>Homo sapiens</i> IGHV5-51*01 (83.70%) -(IGHD)-IGHJ2*01) R120>K (113), L123>T (116) [8.8.14] (1-121) -<i>Homo sapiens</i> IGHG1*01 CH2 P11>I (251), A124>Q (343), CHS K2>del (122-450)], (224-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV3-20*01 (85.40%) -IGKJ2*01) [5.3.9] (1'-106') -<i>Homo sapiens</i> IGKC*01 (107'-213')]; dimère (230-230":233-233")-bisdisulfure</p>

ocaratuzumab

inmunoglobulina G1-kappa, anti-[MS4A1 de *Homo sapiens* (miembro 1 de la subfamilia A de 4 dominios transmembranarios, CD20)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-450) [VH humanizado (*Homo sapiens* IGHV5-51*01 (83.70%) -(IGHD)-IGHJ2*01) R120>K (113), L123>T (116) [8.8.14] (1-121) -*Homo sapiens* IGHG1*01 CH2 P11>I (251), A124>Q (343), CHS K2>del (122-450)], (224-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV3-20*01 (85.40%) -IGKJ2*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01 (107'-213')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGESLKI SCRGSGRFTT SYNMHWVRQM PGKGLEWMMGA 50
IYPLTGDTSY NQKSKLQVTI SADKSISTAY LQWSSLKASD TAMYCARST 100
YVGGDQWFDV WKGKTTVTVS SASTKGPVSF PLAPSSKSTS GGTAALGCLV 150
KDYFPEPVTV SWNSGALTSV VHTFFPAVLQS SGLYLSLSSV TVPSSSLGTQ 200
TYICNVNHPK SNTKVDKKEV PKSCDRHTHC PPCPAPELLG GPSVFLFPK 250
IKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKQKGPFP 350
QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFCSS VMHEALHNNH TQKSLSLSPG 450
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPGT LSLSPGERAT LSCRASSVSP YIHWYQQKPG QAPRLLIYAT 50
SALASGIPDR FSGSGSGTDF TLTISRLEPE DFAVYVCQQW LSNPPTFGQG 100
TKLEIKRTVA APSVFIFFPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYSLSSLTLL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC 213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22"-96" 148"-204" 265"-325" 371"-429"
22"-96" 148"-204" 265"-325" 371"-429"
Intra-L 23"-87" 133"-193"
23"-87" 133"-193"
Inter-H-L 224-213' 224"-213"
Inter-H-H 230-230" 233-233"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
301, 301"

omarigliptinum

omarigliptin


(2*R*,3*S*,5*R*)-2-(2,5-difluorophenyl)-5-[2-(methanesulfonyl)-4,6-dihydropyrrolo[3,4-*c*]pyrazol-5(2*H*)-yl]oxan-3-amine

omarigliptine

(2*R*,3*S*,5*R*)-2-(2,5-difluorophényl)-5-[2-(méthanesulfonyl)-4,6-dihydropyrrolo[3,4-*c*]pyrazol-5(2*H*)-yl]oxan-3-amine

omarigliptina

(2*R*,3*S*,5*R*)-2-(2,5-difluorofenil)-5-[2-(metanosulfonyl)-4,6-dihidropirrol[3,4-*c*]pirazol-5(2*H*)-il]oxan-3-amina

 $C_{17}H_{20}F_2N_4O_3S$


oprozomibum

oprozomib


O-methyl-N-(2-methyl-1,3-thiazol-5-carbonyl)-L-seryl-O-methyl-N-((2*S*)-1-[(2*R*)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl)-L-serinamide

oprozomib

O-méthyl-N-(2-méthyl-1,3-thiazol-5-carbonyl)-L-séryl-O-méthyl-N-((2*S*)-1-[(2*R*)-2-méthyloxiran-2-yl]-1-oxo-3-phénylpropan-2-yl)-L-sérinamide

oprozomib

O-metil-N-(2-metil-1,3-tiazol-5-carbonil)-L-seril-O-metil-N-[(2S)-1-[(2R)-2-metiloxiran-2-il]-1-oxo-3-fenilpropan-2-il]-L-serinamida

C₂₅H₃₂N₄O₇Sorticumabum #
orticumab

immunoglobulin G1-lambda, anti-[*Homo sapiens* oxLDL (oxidized low-density lipoprotein (LDL), malondialdehyde (MDA)-modified apolipoprotein (apo) B-100)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-23*01 (89.80%) -(IGHD)-IGHJ4*01 [8.8.14] (1-121) -IGHG1*01 (122-451)), (224-215')-disulfide with lambda light chain (1'-216')] [*Homo sapiens* V-LAMBDA (IGLV1-47*02 (89.80%) -IGLJ3*02 [8.3.11] (1'-110') -IGLC2*01 (111'-216'))]; (230-230":233-233")-bisdisulfide dimer

orticumab

immunoglobuline G1-lambda, anti-[*Homo sapiens* oxLDL (lipoprotéine de faible densité (LDL) oxydée, apolipoprotéine (apo) B-100 modifiée par la malondialdéhyde (MDA))], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (89.80%) -(IGHD)-IGHJ4*01 [8.8.14] (1-121) -IGHG1*01 (122-451)), (224-215')-disulfure avec la chaîne légère lambda (1'-216')] [*Homo sapiens* V-LAMBDA (IGLV1-47*02 (89.80%) -IGLJ3*02 [8.3.11] (1'-110') -IGLC2*01 (111'-216'))]; dimère (230-230":233-233")-bisdisulfure

orticumab

immunoglobulina G1-lambda, anti-[oxLDL de *Homo sapiens* (lipoproteína de baja densidad (LDL) oxidada, apolipoproteína (apo) B-100 modificada por malondialdehído (MDA))], anticuerpo monoclonal de *Homo sapiens*; cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (89.80%) -(IGHD)-IGHJ4*01 [8.8.14] (1-121) -IGHG1*01 (122-451)), (224-215')-disulfuro con la cadena ligera lambda (1'-216')] [*Homo sapiens* V-LAMBDA (IGLV1-47*02 (89.80%) -IGLJ3*02 [8.3.11] (1'-110') -IGLC2*01 (111'-216'))]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS NAWMSWVQA PGKGLEWVSS 50
ISVGHRTYY ADSVGRSTI SRDnskntly LQMNslraed TAVYCARIR 100
VGPSSGAFDY WQGGTLTVTS SASTKGPSVF PLAPSSKSTS GGTALGCLV 150
KDYFPEPVTV SWNSGALTSV VHTFFAVLQS SGLYSLSSVV TVPSSSLGTQ 200
TYICNVNHKP SNTKVDKVE PKSCDKTHTC PCCPAPPELLG GPSVFLFPFK 250
PKDTRMISR T PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
NSTYRVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP 350
QVYTLPPSRD ELTRKQVSLT CLVKGFPYPSD IAVEWESNGQ PENNYKTPPP 400
VLDSDGSFFL YSKLTVDKSR WQQGNVFCSS VMHEALHNY TQKSLSLSPG 451
K
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQPPSA SGTFGQRTVI SCSGSNTNIG KNYVSWYQQL PGTAPKLLIY 50
ANSNRPSPGVP DRFSGSKSGT SASLAISGLR SEDEADYCA SWDASLNGWV 100
FGGGTKLTVL GQPKAAPSVT LFPPSSSEELQ ANKATLVCLI SDFYPGAVTV 150
AWKADSSPVK AGVETTTPSK QSNKYAASS YLSLTPEQWK SHRSYSCQVT 200
HEGSTVEKTV APTECS 216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22-96 148-204 265-325 371-429
          22"-96" 148"-204" 265"-325" 371"-429"
Intra-L 22-89" 138"-197"
          22"-89" 138"-197"
Inter-H-L 224-215' 224"-215"
Inter-H-H 230-230" 233-233"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
301, 301"

parsatuzumabum #
parsatuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFL7 (epidermal growth factor (EGF)-like repeat superfamily member 7, EGF-like-domains protein 7)], humanized monoclonal antibody;
gamma1 heavy chain (1-453) [humanized VH (*Homo sapiens* IGHV3-74*01 (80.60%) -(IGHD)-IGHJ6*01 T123>L (118) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 CH1 R120>K (220) (124-453)], (226-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (232-232":235-235")-bisdisulfide dimer

parsatuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFL7 (membre 7 de la superfamille des protéines à domaines répétés facteur de croissance épidermique (EGF)-like, protéine 7 à domaines EGF-like)], anticorps monoclonal humanisé;
chaîne lourde gamma1 (1-453) [VH humanisé (*Homo sapiens* IGHV3-74*01 (80.60%) -(IGHD)-IGHJ6*01 T123>L (118) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 CH1 R120>K (220) (124-453)], (226-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dimère (232-232":235-235")-bisdisulfure

parsatuzumab

immunoglobulina G1-kappa, anti-[EGFL7 de *Homo sapiens* (miembro 7 de la superfamilia de proteínas de dominios repetidos factor de crecimiento epidérmico (EGF)-like, proteína 7 de dominios EGF-like)], anticuerpo monoclonal humanizado;
cadena pesada gamma1 (1-453) [VH humanizada (*Homo sapiens* IGHV3-74*01 (80.60%) -(IGHD)-IGHJ6*01 T123>L (118) [8.8.16] (1-123) -*Homo sapiens* IGHG1*03 CH1 R120>K (220) (124-453)], (226-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizada (*Homo sapiens* IGKV1-39*01 (81.00%) -IGKJ1*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCAASGYTFI DYYMNWVRQA PGKLEWVGD 50
INLDSNGTHY NQKFKGRFTI SRDKSKNTAY LQMSLRAED TAVYYCAREG 100
VYHDYDDYAM DYWGQGLTIVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYDFPEPV TVSWNSGALT SGVHTFFPAVL QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KPSNTKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
FKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTIVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSL 450
PGK 453
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGRVIT ITCRTSQSLV HINAITYLHW YQKFKGKAPK 50
LLIYRVSNRF SGVPSRFSGS GSGTDFTLTI SSLQPEDFAT YFCGQSTHVP 100
LTPFGQTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK 150
VQWKVDNALQ SGNSQESVTE QDSKDYSTYSL SFTLTLTKAD YEKHKVYACE 200
VTHQGLSSPV TKSFNREGC 219
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```
Intra-H 22-96 150-206 267-327 373-431
          22"-96" 150"-206" 267"-327" 373"-431"
Intra-L 23-93 139-199"
          23"-93" 139"-199"
Inter-H-L 226-219' 226"-219"
Inter-H-H 232-232" 235-235"
```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
303, 303"

pefcalcitolum


pefcalcitol

2-[[[(1*S*,3*R*,5*Z*,7*E*,20*S*)-1,3-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20-yl]oxy]-*N*-(2,2,3,3,3-pentafluoropropyl)acetamide

pefcalcitol

2-[[[(1*S*,3*R*,5*Z*,7*E*,20*S*)-1,3-dihydroxy-9,10-secopregna-5,7,10(19),16-tetraen-20-yl]oxy]-*N*-(2,2,3,3,3-pentafluoropropyl)acétamide

pefcalcitol

2-[[[(1*S*,3*R*,5*Z*,7*E*,20*S*)-1,3-dihidroxi-9,10-secopregna-5,7,10(19),16-tetraen-20-il]oxi]-*N*-(2,2,3,3,3-pentafluoropropil)acetamidaC₂₆H₃₄F₅NO₄**perakizumabum #**

perakizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A)], humanized monoclonal antibody; gamma1 heavy chain (1-452) [humanized VH (*Homo sapiens*IGHV3-7*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01 CH2 L1.3>A (239), L1.2>A (240) (123-452)], (225-215')-disulfide with kappa light chain (1'-215') [humanized V-KAPPA (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; (231-231":234-234")-bisdisulfide dimer

perakizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-452) [VH humanisé (*Homo sapiens*IGHV3-7*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01 CH2 L1.3>A (239), L1.2>A (240) (123-452)], (225-215')-disulfure avec la chaîne légère kappa (1'-215') [V-KAPPA humanisé (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dimère (231-231":234-234")-bisdisulfure

perakizumab

inmunoglobulina G1-kappa, anti-[IL17A de *Homo sapiens* (interleukina 17A, IL-17A)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-452) [VH humanizado (*Homo sapiens*IGHV3-7*01 (90.80%) -(IGHD)-IGHJ4*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01 CH2 L1.3>A (239), L1.2>A (240) (123-452)], (225-215')-disulfuro con la cadena ligera kappa (1'-215') [V-KAPPA humanizado (*Homo sapiens* IGKV1-16*01 (82.10%) -IGKJ2*01) [6.3.10] (1'-108') -*Homo sapiens* IGKC*01 (109'-215')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGG LVQPGGSLRL SCAASGFTFS DYTMLWVRQA PGKGLEWVAI 50
 IKSGGSYQY PDSVKGRFTI SRDNAKNSLY LQMSLRAED TAVYVCARDG 100
 DYSSSYGAM YWQGTTLVTV SSASTKGFVS FPLAFSSKST SGGTAALGCL 150
 VKDYFFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTVSSSLGT 200
 QTYICNVNHK PSNTKVDKVV EPKSCDKTHT CPPCPAPEAA GGPSVFLFPP 250
 KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NQYVDGVEVH NAKTKPREEQ 300
 YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
 PQVYTLPPSR DELTKNQVSL TCLVKGFPYS DIAVEWESNG QPENNYKTFP 400
 PVLDSDSGFF LYSKLTVDKS RWQQGNVFC SVMHEALHNN YTKKSLSLSP 450
 GK 452

Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS LSASVGDRVT ITCRASQDIN SYLSWFQKPK GKAPKSLIVR 50
 ANRLVDGVPV RFGSGSGQD YSLTISSLQP EDFATYYCLQ YDAFFPYTFG 100
 QGTKLEIKRT VAAPSVFIFP PSDEQLKSGT ASVVCLLNNF YFREAKVQWK 150
 VDNALQSGNS QESVTEQDSK DSTYLSSTL TSKADYEKH KVIACEVTHQ 200
 GLSSPVTKSF NRGEC 215

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H 22-96 149-205 266-326 372-430
 22"-96" 149"-205" 266"-326" 372"-430"
 Intra-L 23"-88" 135"-195"
 23"-88" 135"-195"
 Inter-H-L 225-215" 225"-215"
 Inter-H-H 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 302, 302"

pictilisibum
 pictilisib

2-{1*H*-indazol-4-yl}-6-[[4-(methanesulfonyl)piperazin-1-yl]methyl]-4-(morpholin-4-yl)thieno[3,2-*d*]pyrimidine


pictilisib

2-(1*H*-indazol-4-yl)-6-[[4-(méthanesulfonyl)pipérazin-1-yl]méthyl]-4-(morpholin-4-yl)-thiéno[3,2-*d*]pyrimidine

pictilisib


2-{1*H*-indazol-4-il}-6-[[4-(metanosulfoñil)piperazin-1-il]metil]-4-(morfolin-4-il)tiéno[3,2-*d*]pirimidina


C₂₃H₂₇N₇O₃S₂



placulumabum #
 placulumab

immunoglobulin (V-kappa)2-Fc gamma1, anti-[*Homo sapiens* TNF (tumor necrosis factor, TNF superfamily member 2, TNFSF2, TNF-alpha, TNFA)], *Homo sapiens* monoclonal antibody;
 V-kappa -(CH1>del) gamma1 chain (1-341) [*Homo sapiens* V-KAPPA (IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1-107) -IGHG1*01 [CH1 1.4-119>del, K120>R (108) (108-109), hinge 1-15 C5>S (114) (110-124), CH2 (125-234), CH3 (235-339), CHS (340-341)]; (120-120':123-123')-bisdisulfide dimer

placulumab	immunoglobuline (V-kappa)2-Fc gamma1, anti-[<i>Homo sapiens</i> TNF (facteur de nécrose tumorale, membre 2 de la superfamille du TNF, TNFSF2, TNF-alpha, TNFA)], <i>Homo sapiens</i> anticorps monoclonal; chaîne V-kappa -(CH1>del) gamma1 (1-341) [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1-107) -IGHG1*01 [CH1 1.4-119>del, K120>R (108) (108-109), charnière 1-15 C5>S (114) (110-124), CH2 (125-234), CH3 (235-339), CHS (340-341)]; dimère (120-120':123-123')-bisdisulfure
placulumab	inmunoglobulina (V-kappa)2-Fc gamma1, anti-[TNF de <i>Homo sapiens</i> (factor de necrosis tumoral, miembro 2 de la superfamilia del TNF, TNFSF2, TNF-alfa, TNFA)], anticuerpo monoclonal de <i>Homo sapiens</i> ; cadena V-kappa -(CH1>del) gamma1 (1-341) [<i>Homo sapiens</i> V-KAPPA (IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1-107) -IGHG1*01 [CH1 1.4-119>del, K120>R (108) (108-109), bisagra 1-15 C5>S (114) (110-124), CH2 (125-234), CH3 (235-339), CHS (340-341)]; dímero (120-120':123-123')-bisdisulfuro Heavy chain / Chaîne lourde / Cadena pesada DIQMTQSPSS LSASVGRVIT ITCRASQAID SYLHWYQQKP GKAPKLLIYS 50 ASNLETGVPS RFGSGSGTDT FTLTISLLP EDFATYYCQQ VVWRPFTFGQ 100 GTKVETKRVE PKSSDKHTC PCCPAPELLG GPSVFLFPPK PKDTLMSRT 150 PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY NSTYRVVSVL 200 TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP QVYTLPPSRD 250 ELTKNQVSLT CLVKGFPYSD IAVWEWSNGQ PENNYKTTTP VLDSGDGFFL 300 YSKLTVDKSR WQQGNVFCSS VMHEALHNHY TQKLSLSLSPG K 341 Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H 23-88 155-215 261-319 23'-88' 155'-215' 261'-319' Inter-H-H 120-120' 123-123' N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 191, 191'
pocapavirum pocapavir	1,3-dichloro-2-((4-((2-chloro-4-methoxyphenoxy)methyl)phenyl)methoxy)benzene
pocapavir	1,3-dichloro-2-((4-((2-chloro-4-méthoxyphénoxy)méthyl)phényl)méthoxy)benzene
pocapavir	1,3-dicloro-2-((4-((2-cloro-4-metoxifenoxi)metil)fenil)metoxi)benceno C ₂₁ H ₁₇ Cl ₃ O ₃ 
pradimotidum pradimotide	human vascular endothelial growth factor receptor 1 (VEGFR-1)-(1058-1066)-peptide
pradimotide	récepteur 1 du facteur de croissance de l'endothélium vasculaire humain (VEGFR-1)-(1058-1066)-peptide
pradimotida	receptor 1 del factor de crecimiento endotelial vascular humano (VEGFR-1)-(1058-1066)-péptido



H-Ser-Tyr-Gly-Val-Leu-Leu-Trp-Glu-Ile-OH

quisinostatam

quisinostat



N-hydroxy-2-[4-({[(1-méthyl-1*H*-indol-3-yl)méthyl]amino)méthyl]piperidin-1-yl]pyrimidine-5-carboxamide

quisinostat

N-hydroxy-2-[4-({[(1-méthyl-1*H*-indol-3-yl)méthyl]amino)méthyl]pipéridin-1-yl]pyrimidine-5-carboxamide

quisinostat

N-hidroxi-2-[4-({[(1-metil-1*H*-indol-3-il)metil]amino)metil]piperidin-1-il]pirimidina-5-carboxamida

**rabusertibum**

rabusertib



1-(2-chloro-3-fluorophenyl)-3-[4-chloro-2-hydroxy-3-(piperazine-1-sulfonyl)phenyl]urea

rabusertib

1-(5-bromo-4-méthyl-2-((2*S*)-morpholin-2-yl)méthoxy)phényl)-3-(5-méthylpyrazin-2-yl)urée

rabusertib

1-(2-cloro-3-fluorofenil)-3-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonyl)fenil]urea

**relugolixum**

relugolix


1-(4-{1-[(2,6-difluorophenyl)méthyl]-5-[(diméthylamino)méthyl]-3-(6-méthoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tétrahydrothiéno[2,3-d]pyrimidin-6-yl}phényl)-3-méthoxyurea

rélugolix

1-(4-{1-[(2,6-difluorophényl)méthyl]-5-[(diméthylamino)méthyl]-3-(6-méthoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tétrahydrothiéno[2,3-d]pyrimidin-6-yl}phényl)-3-méthoxyurea

relugolix

1-(4-{1-[(2,6-difluorofenil)metil]-5-[(dimetilamino)metil]-3-(6-metoxipiridazin-3-il)-2,4-dioxo-1,2,3,4-tetrahidrotieno[2,3-d]pirimidin-6-il}fenil)-3-metoxiurea

C₂₉H₂₇F₂N₇O₅S**rilimogenum galvacirepvecum #**

rilimogene galvacirepvec

recombinant replicating vaccinia viral vector expressing a modified prostate specific antigen (PSA) plus three co-stimulatory molecules, lymphocyte associated function antigen-3 (LFA-3), intracellular adhesion molecule-1 (ICAM-1) and B7.1.

rilimogène galvacirépvec

vecteur viral recombinant de la vaccine répliquant exprimant un antigène modifié spécifique de la prostate et trois protéines co-stimulantes (antigène 3 associé aux fonctions lymphocytaires (LFA-3), molécule d'adhésion intracellulaire-1 (ICAM-1) et B7.1)

rilimogén galvacirepvec

vector viral recombinante de la vacuna replicante que expresa un antigéno modificado específico prostático y tres proteínas co-stimulantes (antigéno 3 asociado a las funciones limfocitarias (LFA-3), molécula d'adhésion intracelular-1 (ICAM-1) y B7.1)

rilimogenum glafolivecum #

rilimogene glafolivec

recombinant non-replicating fowlpox viral vector expressing a modified prostate specific antigen (PSA) plus three co-stimulatory molecules, lymphocyte associated function antigen-3 (LFA-3), intracellular adhesion molecule-1 (ICAM-1) and B7.1

rilimogène glafolivec

vecteur viral recombinant non-répliquant de la variole aviaire exprimant un antigéno modifié spécifique de la prostate et trois protéines co-stimulantes (antigéno 3 associé aux fonctions lymphocytaires (LFA-3), molécule d'adhésion intracellulaire-1 (ICAM-1) et B7.1)

rilimogén glafolivec

vector viral recombinante no-replicante de la viruela aviar que expresa un antigéno modificado específico prostático y tres proteínas co-stimulantes (antigéno 3 asociado a las funciones limfocitarias (LFA-3), molécula d'adhésion intracelular-1 (ICAM-1) y B7.1)

rovatirelinum


rovatirelin

(4*S*,5*S*)-5-methyl-*N*-{(2*S*)-1-[(2*R*)-2-methylpyrrolidin-1-yl]-1-oxo-3-[(1,3-thiazol-4-yl)methyl]propan-2-yl}-2-oxo-1,3-oxazolidine-4-carboxamide

rovatiréline

(4*S*,5*S*)-5-méthyl-*N*-{(2*S*)-1-[(2*R*)-2-méthylpyrrolidin-1-yl]-1-oxo-3-[(1,3-thiazol-4-yl)méthyl]propan-2-yl}-2-oxo-1,3-oxazolidine-4-carboxamide

rovatirelina

4*S*,5*S*-5-méthyl-*N*-[(2*S*)-1-[(2*R*)-2-méthylpirrolidin-1-yl]-1-oxo-3-[(1,3-tiazol-4-yl)méthyl]propan-2-yl]-2-oxo-1,3-oxazolidina-4-carboxamideC₁₆H₂₂N₄O₄Ssebelipasum alfa #
sebelipase alfahuman lysosomal acid lipase/cholesterol ester hydrolase (cholesterol esterase, lipase A, EC=3.1.1.13) glycosylated (produced in transgenic *Gallus*)

sébelipase alfa

lipase acide lysosomale/hydrolase d'esters de cholestérol (cholestéryl estérase, lipase A, EC=3.1.1.13), enzyme humaine glycosylée produite par *Gallus* transgénique

sebelipasa alfa

lipasa ácida lisosómica/hidrolasa de los ésteres de colesterol (colesterol esterasa, lipasa A, EC=3.1.1.13), enzima humana glicosilada producida por *Gallus* transgénico

```

SGGKLTAVDP  ETNMNVSEII  SYWGFPSSEY  LVETEDGYIL  CLNRIPHGRK  50
NHSDKGPKEV  VFLQHGLLAD  SSNWVTNLAN  SSLGFILADA  GFDVWVGNSR  100
GNTWSRKHKT  LSVSQDEFWA  FSYDEMAKYD  LPASINFILN  KTGQEQVYVV  150
GHSQGTITGF  IAFSQIPELA  KRIMFFALG  FVASVAFCTS  PMAKLGRLPD  200
HLIKDLFGDK  EFLPQSAFLK  WLGHVCTHV  ILKELCGNLC  FLLCGFNERN  250
LNMSRVDVYT  THSPAGTSVQ  NMLHWSQAVK  FQKFQAFDWG  SSARNYFHYN  300
QSYPTYNVK  DMLVPTAVWS  GGHDLWLDVY  DVNILLTQIT  NLVFHESIPE  350
WEHLDFIWGL  DAPWRLYNKI  INLMRKYQ  378

```

Disulfide bridges location* / Positions* des ponts disulfure / Posiciones* de los puentes disulfuro
 41-188 227-236 240-244
 * predicted / prévues / previstas

Glycosylation sites (N) / sites de glycosylation (N) / posiciones de glicosilación (N)
 Asn-15 Asn-80 Asn-140 Asn-252 Asn-300

senrebotasum #
senrebotase

L-methionylglycyl-L-seryl-des-(445-glycine,446-L-tyrosine)-[2-L-glutamic acid,432,442,444,447-tetra- L-aspartic acid]botulinum neurotoxin A precursor 27-L-alanine variant light chain (433-41')-disulfide with [14-L-arginine,15-L-lysine]human nociceptin fusion protein with L-alanyl-L-leucyl-L-alanyltris(tetraglycyl-L-seryl)-[3-L-valine,4-L-leucine,5-L-glutamine-418-L-leucine,419-L-aspartic acid]botulinum neurotoxin A heavy chain-(1-419)-peptide

senrébotase

L-méthionylglycyl-L-séryl-dès-(445-glycine,446-L-tyrosine)-[2-L-acide glutamique,432,442,444,447-tétra-L-acide aspartique]chaîne légère du 27-L-alanine-variant du précurseur de la neurotoxine A botulique (433-41')-disulfure avec le [14-L-arginine,15-L-lysine]nociceptine humaine protéine de fusion avec le L-alanyl-L-leucyl-L-alanyltris(tétraglycyl-L-seryl)-[3-L-valine,4-L-leucine,5-L-glutamine-418-L-leucine,419-L-acide aspartique]chaîne lourde de la neurotoxine A botulique-(1-419)-peptide

senrebotasa

L-metionilglicil-L-seril-des-(445-glicina,446-L-tirosina)-[2-L-ácido glutámico,432,442,444,447-tetra-L-ácido aspártico]cadena ligera de la 27-L-alanina-variante del precursor de la neurotoxina botulínica A (433-41')-disulfuro con la [14-L-arginina,15-L-lisina]nociceptina humana proteína de fusión con el L-alanil-L-leucil-L-alaniltris(tetraglicil-L-seril)-[3-L-valina,4-L-leucina,5-L-glutamina-418-L-leucina,419-L-ácido aspártico]cadena pesada de la neurotoxina botulínica A-(1-419)-péptido

Light chain / Chaîne légère / Cadena ligera

MGSMEFVNKQ FNYKDPVNGV DIAYIKIPNA GQMOPVKAFK IHNKIWVIFE 50
 RDTFTNPPEG DLNPPPEAKQ VPVSYDSTY LSTDNEKDNV LKGVTKLFFER 100
 IYSTDLGRML LTSIVRGIPF WGGSTIDTEL KVIDTNCINV IQPDGSRSE 150
 ELNLVIIGPS ADIIQFECKS FGEVVLNLR NGYGSTQYIR FSPDFTFGFE 200
 ESLEVDTNPL LGAGKFATDP AVTLAHELIH AGHRLYGIAI NPNRVFKVNT 250
 NAYYEMSGLE VSFEELRTFG GHDAKFIDSL QNEFRLYYY NKFKDIASL 300
 NKAKSIVGTT ASLQYMKNVF KEKYLLEDSTL SGKFSVDKLL FDKLYKMLTE 350
 IYTEDNEVKE FKVLNRKTYL NFDKAVFKIN IVPKVNYTII DGFNLRNTNL 400
 AANFNGQNT E INNMNFTKLL NFTGLFEFYK LLCVDGIITS KTKSDDDDK 449

Heavy chain / Chaîne lourde / Cadena pesada

FGGFTGARKS ARKRKNQALA GGGSGGGGS GGGGSALVLQ CIKVNNDWLF 50'
 FSPSEDNFTN DLNKGEEITS DTNIEAAEEN ISLDLIQQYY LTFNFDNEPE 100'
 NISLENLSSD IIGQLELMPN IERFPNGKKY ELDKYTMFHY LRAQEFHGCK 150'
 SRIALTNSVN EALLNPSRVY TFFSSDYVKK VNKATEAAMF LGWVEQLVVD 200'
 FTDETSEVST TDKIADITII IPYIGPALNI GNMLYKDDFV GALIFSGAVI 250'
 LLEFIPEIAI PVLGTFALVS YIANKVLTVQ TIDNALSQRN EKWDEVYKYI 300'
 VTNWLAKVNT QIDLIRKKMK EALENQA EAT KAIINYQYNQ YTEEEKNNIN 350'
 FNIDDLSSKL NESINKAMIN INKFLNQC SV SYLMNSMIPY GVKRLEDFFDA 400'
 SLKDALLKYI YDNRGTLIGQ VDRLEKDKVNN TLSTDIPFQL SKYVDNQRLL 450'
 STLD 454'

Disulfide bridge location / Position du pont disulfure / Posición del puente disulfuro
 433-41'

sepranolonum

sepranolone


3β-hydroxy-5α-pregnan-20-one

sépranolone

3β-hydroxy-5α-prégnan-20-one

sepranolona

3β-hidroxi-5α-pregnan-20-ona



C₂₁H₃₄O₂

sintuzumabum #

sintuzumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* LOXL2 (lysyl oxidase-like 2)], humanized monoclonal antibody;
 gamma4 heavy chain (1-443) [humanized VH (*Homo sapiens* IGHV1-2*02 (80.60%) -(IGHD)-IGHJ4*01 L123>T (111) [8.8.9] (1-116) -*Homo sapiens* IGHG4*01 hinge S10>P (224) (117-443)], (130-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (*Homo sapiens* IGKV2D-29*02 (86.00%) -IGKJ4*01) [11.3.9] (1'-112') -*Homo sapiens* IGKC*01 (113'-219')]; (222-222":225-225")-bisdisulfide dimer

simtuzumab	immunoglobuline G4-kappa, anti-[<i>Homo sapiens</i> LOXL2 (protéine 2 lysyl oxidase-like)], anticorps monoclonal humanisé; chaîne lourde gamma4 (1-443) [VH humanisé (<i>Homo sapiens</i> IGHV1-2*02 (80.60%) -(IGHD)-IGHJ4*01 L123>T (111) [8.8.9] (1-116) - <i>Homo sapiens</i> IGHG4*01 charnière S10>P (224) (117-443)], (130-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV2D-29*02 (86.00%) -IGKJ4*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]; dimère (222-222":225-225")-bisdisulfure
simtuzumab	immunoglobulina G4-kappa, anti-[LOXL2 de <i>Homo sapiens</i> (lysyl oxidase-like 2)], anticuerpo monoclonal humanizado; cadena pesada gamma4 (1-443) [VH humanizado (<i>Homo sapiens</i> IGHV1-2*02 (80.60%) -(IGHD)-IGHJ4*01 L123>T (111) [8.8.9] (1-116) - <i>Homo sapiens</i> IGHG4*01 bisagra S10>P (224) (117-443)], (130-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (<i>Homo sapiens</i> IGKV2D-29*02 (86.00%) -IGKJ4*01) [11.3.9] (1'-112') - <i>Homo sapiens</i> IGKC*01 (113'-219')]; dímero (222-222":225-225")-bisdisulfuro
	<p>Heavy chain / Chaîne lourde / Cadena pesada</p> <p>QVQLVQSGAE VKKPGASVKV SCKASGYAFT YYLIEWVRQA PGQGLEWIGV 50 INPFGSGGTNY NEKFKGRATI TADKSTSTAY MELSSLRSED TAVYFCARNW 100 MNFDFYWGQGT TVTVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150 EPVTVSWNSG ALTSVGVHTFP AVLQSSGLYS LSSVTVTPSS SLGKTYTCN 200 VDHKPSNTKV DKRVESKYGP PCPCPAPEF LGGPSVFLFP PKPKDTMLIS 250 RTPETVTCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300 VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKARGQPR EPQVYTLPPS 350 QEEMTKNQVS LTCLVKGFYFP SDIAVEWESN GQFENNYKTT PPVLDSDGSGF 400 FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTQKSLSLG LGR 443</p> <p>Light chain / Chaîne légère / Cadena ligera</p> <p>DIVMTQTPLS LSVTPGQPAS ISCRSSKSLI HSNGNLYLYW FLQKPGQSPQ 50 FLIYRMSNLA SGVPRDFSGS GSGTDFTLKI SRVEAEDVGV YYCMQHLEYP 100 YTFGGGTQVE IKRTVAAPSV FIFPPSDEQL KSGTASVIVCL LNNFYPREAK 150 VQWKVDNALQ SGNSQESVTE QDSKDYSTYL SSTLTLSKAD YEKHKVYACE 200 VTHQGLSSPV TKSFNREGC 219</p> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <p>Intra-H 22-96 143-199 257-317 363-421 22"-96" 143"-199" 257"-317" 363"-421"</p> <p>Intra-L 23'-93' 139"-199" 23"-93"" 139"-199""</p> <p>Inter-H-L 130-219' 130"-219" Inter-H-H 222-222" 225-225"</p> <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 293, 293"</p>
sonidegibum	
sonidegib	<i>N</i> -{6-[(2 <i>R</i> ,6 <i>S</i>)-2,6-diméthylmorpholin-4-yl]pyridin-3-yl}-2-méthyl-4'-(trifluorométhoxy)-[1,1'-biphényl]-3-carboxamide
sonidégeb	<i>N</i> -{6-[(2 <i>R</i> ,6 <i>S</i>)-2,6-diméthylmorpholin-4-yl]pyridin-3-yl}-2-méthyl-4'-(trifluorométhoxy)-[1,1'-biphényl]-3-carboxamide
sonidegib	<i>N</i> -{6-[(2 <i>R</i> ,6 <i>S</i>)-2,6-diméthylmorpholin-4-il]piridin-3-il}-2-metil-4'-(trifluorometoxi)-[1,1'-bifenil]-3-carboxamida

**sonolisibum**



sonolisib

(4*E*)-4-[[bis(prop-2-en-1-yl)amino]methylidene]-6-hydroxy-1α-(methoxymethyl)-3,7,17-trioxo-2-oxaandrosta-5,8-dien-11α-yl acetate

sonolisib

acétate de (4*E*)-4-[[bis(prop-2-én-1-yl)amino]méthylidène]-6-hydroxy-1α-(méthoxyméthyl)-3,7,17-trioxo-2-oxaandrosta-5,8-dién-11α-yle

sonolisib

acetato de (4*E*)-4-[[bis(prop-2-en-1-il)amino]metilideno]-6-hidroxi-1α-(metoximetil)-3,7,17-trioxo-2-oxaandrosta-5,8-dien-11α-ilo**surotomycinum**



surotomycin

N-[[2*E*]-3-(4-pentylphenyl)but-2-enoyl]-L-tryptophyl-D-asparaginyl-L-α-aspartyl-L-threonylglycyl-L-ornithyl-L-α-aspartyl-D-alanyl-L-α-aspartylglycyl-D-seryl-(3*R*)-3-methyl-L-α-glutamyl-3-(2-aminobenzoyl)-L-alanine 13→4-lactone

surotomycine

N-[[2*E*]-3-(4-pentylphényl)but-2-énoyl]-L-tryptophyl-D-asparaginyl-L-α-aspartyl-L-thréonylglycyl-L-ornithyl-L-α-aspartyl-D-alanyl-L-α-aspartylglycyl-D-séryl-(3*R*)-3-méthyl-L-α-glutamyl-3-(2-aminobenzoyl)-L-alanine 13→4-lactone

surotomicina

N-[[2*E*]-3-(4-pentilfenil)but-2-enoil]-L-triptofil-D-asparaginil-L-α-aspartil-L-treonilglicil-L-ornitil-L-α-aspartil-D-alanil-L-α-aspartilglicil-D-seril-(3*R*)-3-metil-L-α-glutamil-3-(2-aminobenzoi)-L-alanina 13→4-lactona

technetium (^{99m}Tc) etarfolatidum
technetium (^{99m}Tc) etarfolatide

(SPY-5-24)-[N²-(4-[[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino]benzoyl)-D-γ-glutamyl-(2S)-2-(amino-κN)-β-alanyl-L-α-aspartyl-κN-L-cysteinato-κN,κS]oxido[^{99m}Tc]technetate


technétium (^{99m}Tc) étarfolatide

(SPY-5-24)-[N²-(4-[[[(2-amino-4-oxo-1,4-dihydroptéridin-6-yl)méthyl]amino]benzoyl)-D-γ-glutamyl-(2S)-2-(amino-κN)-β-alanyl-L-α-aspartyl-κN-L-cystéinato-κN,κS]oxido[^{99m}Tc]technétate

tecnecio (^{99m}Tc) etarfolatida

(SPY-5-24)-[N²-(4-[[[(2-amino-4-oxo-1,4-dihydropteridin-6-il)metil]amino]benzoil)-D-γ-glutamyl-(2S)-2-(amino-κN)-β-alanyl-L-α-aspartil-κN-L-cisteinato-κN,κS]oxido[^{99m}Tc]tecnecetato

C₂₉H₃₂N₁₁O₁₂STc



tenapanorum
tenapanor

N,N-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosane-1,26-diyl)bis[[(4*S*)-6,8-dichloro-2-methyl-1,2,3,4-tetrahydroisoquinolin-4-yl]benzenesulfonamide}


ténapanor

N,N-(10,17,-dioxo-3,6,21,24-tétraoxa-9,11,16,18-tétraazahexacosane-1,26-diyl)bis[[(4*S*)-6,8-dichloro-2-méthyl-1,2,3,4-tétrahydroisoquinoléin-4-yl]benzènesulfonamide}

tenapanor

N,N-(10,17,-dioxo-3,6,21,24-tetraoxa-9,11,16,18-tetraazahexacosano-1,26-diol)bis[[(4*S*)-6,8-dicloro-2-metil-1,2,3,4-tetrahydroisoquinolin-4-il]bencenosulfonamida}

C₅₀H₆₆Cl₄N₈O₁₀S₂



trabodenosonum
trabodenoson



*N*⁶-cyclopentyladenosine 5'-nitrate

trabodénoson

5'-nitrate de *N*⁶-cyclopentyladénosine

trabodenosón

5'-nitrato de *N*⁶-ciclopentiladenosina

**trempamotidum**

trempamotide

human kinesin like protein KIF20B (M phase phosphoprotein 1)-(278-286)-peptide

trempamotide

membre 20B des protéines de la famille des kinésines humaines (phosphoprotéine 1 de la phase M)-(278-286)-peptide

trempamotida

miembro 20B de las proteínas de la familia de las kinesinas humanas (fosfoproteína 1 de la fase M)-(278-286)-péptido



H-Ile-Tyr-Asn-Glu-Tyr-Ile-Tyr-Asp-Leu-OH

trenonacogum alfa #

trenonacog alfa

human coagulation factor IX (EC 3.4.21.22, Christmas factor, plasma thromboplastin component), 148-threonine variant, produced in Chinese Hamster Ovary (CHO) cells (alfa glycoform)

trénonacog alfa

variant 148-thréonine du facteur IX humain de coagulation (EC 3.4.21.22, facteur Christmas, facteur antihémophilique B) produit par culture de cellules ovariennes de hamster chinois (CHO) (glycoforme alfa)

trenonacog alfa

148-treonina-variante del factor IX humano de la coagulación sanguínea (EC 3.4.21.22, factor Christmas, factor antihemofílico B) producido por cultivo de células ováricas de hamster chinos (CHO) (glicofoma alfa)

```


YNSGKLEEFV QGNLERECME EKCSFEEARE VFENTERTTE FWKQYVDGDQ 50
CESNPCLNGG SCKDDINSYE CWCPFGFEGK NCELDVTCNI KNGRCEQFCK 100
NSADNKVVC S CTEGYRLAEN QKSCFPAVFP PCGRVSVSQT SKLTRAETVF 150
PDVDYVNSTE AETILDNI TQ STQSFNDFTR VVGGEDAKPG QFPWQVVLNG 200
KVDAFCGGSI VNEKWI VTAA HCVETGVKIT VVAGEHNIEE TEHTEQKRVN 250
IRIIPHNNYN AAINKYNHDI ALLELDEPLV LNSYVTPICI ADKEYTNIFL 300
KFGSGYVSCW GRVFKGRSA LVLQYLRVPL VDRATCLRST KFTIYNNMFC 350
AGFHEGGGRD S CQGDSSGGPHV TEVEGTSFLT GIISWGEECA MKGRYGIYTK 400
VSRVYNWIK E KTKLT 415

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 18-23 51-62 56-71 73-82 88-99 95-109
 111-124 132-289 206-222 336-350 361-389

Modified residues / Résidus modifiés / Restos modificados

E
 7-8-15-17-20-21-26-27-30-33-36-40
 4-carboxyGlu



Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
 Asn-157 Asn-167

trifarotenum

trifarotene


3''-tert-butyl-4'-(2-hydroxyethoxy)-4''-(pyrrolidin-1-yl)[1,1':3',1'']terphenyl-4-carboxylic acid

trifarotène

acide 3''-tert-butyl-4'-(2-hydroxyéthoxy)-4''-(pyrrolidin-1-yl)[1,1':3',1'']terphényl-4-carboxylique

trifaroteno

ácido 3''-terc-butil-4'-(2-hidroxietoxi)-4''-(pirrolidin-1-il)[1,1':3',1'']terfenil-4-carboxílico

C₂₉H₃₃NO₄**vercirnonum**

vercirnon


4-[5-chloro-2-(4-tert-butylbenzenesulfonamido)benzoyl]pyridine N-oxide

vercirnon

4-[5-chloro-2-(4-tert-butylbenzènesulfonamido)benzoyl]pyridine N-oxide

vercirnón

N-óxido de 4-[5-cloro-2-(4-terc-butilbencenosulfonamido)benzoil]piridina

C₂₂H₂₁ClN₂O₄S**vintafolidum #**

vintafolide


N-(4-[[[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)méthyl]amino]benzoyl]-L-γ-glutamyl-L-α-aspartyl-L-arginyl-L-α-aspartyl-L-α-aspartyl-L-cysteine disulfide with methyl (5S,7R,9S)-5-ethyl-9-[(3aR,4R,5S,5aR,10bR,13aR)-3a-ethyl-4,5-dihydroxy-8-methoxy-6-méthyl-5-[[2-[[2-sulfanylethoxy]carbonyl]hydrazinyl]carbonyl]-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-9-yl]-5-hydroxy-1,4,5,6,7,8,9,10-octahydro-2H-3,7-methanoazacycloundécino[5,4-b]indol-9-carboxylate

vintafolide

N-(4-[[[(2-amino-4-oxo-1,4-dihydroptéridin-6-yl)méthyl]amino]benzoyl]-L-γ-glutamyl-L-α-aspartyl-L-arginyl-L-α-aspartyl-L-α-aspartyl-3-[2-[2-[[2-[[[(3aR,4R,5S,5aR,10bR,13aR)-3a-éthyl-9-[(5S,7R,9S)-5-éthyl-5-hydroxy-9-(méthoxycarbonyl)-1,4,5,6,7,8,9,10-octahydro-2H-3,7-méthanoazacycloundécino[5,4-b]indol-9-yl]-4,5-dihydroxy-8-méthoxy-6-méthyl-3a,4,5,5a,6,11,12,13a-octahydro-1H-indolizino[8,1-cd]carbazol-9-yl]carbonyl]hydrazino]carbonyl]oxy]éthyl]disulfanyl]-L-alanine

vintafolida

N-(4-[[[(2-amino-4-oxo-1,4-dihydropteridina-6-il)metil]amino]benzoi]-L-γ-glutamil-L-α-aspartil-L-arginil-L-α-aspartil-L-α-aspartil-3-{2-[2-[[[2-[[[3a*R*,4*R*,5*S*,5a*R*,10b*R*,13a*R*]-3a-etil-9-[[5*S*,7*R*,9*S*]-5-etil-5-hidroxi-9-(metoxicarbonil)-1,4,5,6,7,8,9,10-octahidro-2*H*-3,7-metanoazacicloundecino[5,4-*b*]indol-9-il]-4,5-dihidroxi-8-metoxi-6-metil-3a,4,5,5a,6,11,12,13a-octahidro-1*H*-indolizino[8,1-*cd*]carbazol-9-il]carbonil)hidrazino]carbonil]oxi]etil]disulfanil]-L-alanina



vocimagenum amiretrorepevum #
vocimagine amiretrorepevec

recombinant replication-competent retrovirus vector encoding a human codon optimized yeast cytosine deaminase gene, carrying three stabilizing point mutations (A23L/ V108T/ I140L) and translated via an EMCV IRES (encephalomyocarditis virus internal ribosomal entry site)

vocimagène amirétrorépvec

vecteur rétroviral recombinant répliquant codant le gène de la cytosine désaminase de levure optimisé par des codons humains, comprenant trois points de mutations stabilisants (A23L/ V108T/ I140L) et traduit sous le contrôle de la séquence IRES (site d'entrée interne du ribosome) du virus de l'encéphalomyocardite (EMCV)

vocimagén amiretrorepevec

vector retroviral recombinante replicante que codifica el gen de la citosina desaminasa de levadura optimizada por codones humanos, que comprende tres puntos de mutaciones estabilizadores (A23L/ V108T/ I140L) y traducido bajo el control de la secuencia IRES (sitio de entrada interna del ribosoma) del virus de la encefalomiocarditis (EMCV)

vorsetuzumabum #
vorsetuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* CD70 (tumor necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L)], humanized monoclonal antibody; gamma1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; (227-227":230-230")-bisdisulfide dimer

vorsétuzumab immunoglobuline G1-kappa, anti-[*Homo sapiens* CD70 (membre 7 de la superfamille du facteur de nécrose tumorale (TNF), TNFSF7, CD27LG, CD27L)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-448) [VH humanisé (*Homo sapiens* IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-218'-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dimère (227-227":230-230")-bisdisulfure

vorsetuzumab inmunoglobulina G1-kappa, anti-[CD70 de *Homo sapiens* (miembro 7 de la superfamilia del factor de necrosis tumoral (TNF), TNFSF7, CD27LG, CD27L)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-448) [VH humanizado (*Homo sapiens* IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-218'-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizada (*Homo sapiens* IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKASGYFT NYGMNWRQA PGQGLKWMGW 50
 INTYTGEPY ADAFKGRVTM TRDTSISTAY MELSRRLSDD TAVYVCARDY 100
 GDYGMIDYWGQ GTTIVTSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
 FPEFVTVSWN SGALTSVHT FPAVLQSSGL YLSLVVTVV SSSLGTQTYI 200
 CNVNHKPSNT KVDKKVEPKS CDKTHCTCPPE PAVELGQPS VFLFPPKPKD 250
 TLMISRTPEV TCVVVDVSHS DPEVKFNWYV DGEVFNHAKT KPREEQYNST 300
 YRVVSVLTVL HQDMLNGKEY KCKVSNKALP APIEKTISKA KGQPREPQVY 350
 LTPPSRDELDT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTFFVLD 400
 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS LAVSLGERAT INCRASKSVS TSGYSFMHWY QQKPGQPPKL 50
 LIYLASNLES GVPDRFSGSG SGTDFLTIS SLQAEDVAVY YCQHSREVPW 100
 TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
 QWKVDNALQS GNSQESVTEQ DSKDSTYLSL STLTLKADY EKHKVYACV 200
 THQGLSSPVT KSFNRGEC 218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H 22-96 145-201 262-322 368-426
 22"-96" 145"-201" 262"-322" 368"-426"
 Intra-L 23'-92' 138'-198'
 23"'-92'" 138"'-198'"
 Inter-H-L 221-218' 221"-218"
 Inter-H-H 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 298, 298"

vorsetuzumabum mafodotinum #
 vorsetuzumab mafodotin

immunoglobulin G1-kappa auristatin F conjugate, anti-[*Homo sapiens* CD70 (tumor necrosis factor superfamily member 7, TNFSF7, CD27LG, CD27L)], humanized monoclonal antibody conjugated to auristatin F; gamma 1 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*01 (119-448)], (221-218')-disulfide (if not conjugated) with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01 (112'-218')]; (227-227":230-230")-bisdisulfide dimer; conjugated, on an average of 3 to 5 cysteinyl, to monomethylauristatin F (MMAF), via a noncleavable maleimidocaproyl (mc) linker
 For the *mafodotin* part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others".

vorsétuzumab mafodotine	<p>immunoglobuline G1-kappa conjuguée à l'auristatine F, anti-[<i>Homo sapiens</i> CD70 (membre 7 de la superfamille du TNF, TNFSF7, CD27LG, CD27L)], anticorps monoclonal humanisé conjugué à l'auristatine F;</p> <p>chaîne lourde gamma1 (1-448) [VH humanisé (<i>Homo sapiens</i>IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -<i>Homo sapiens</i>IGHG1*01 (119-448)], (221-218'-disulfure (si non conjugué) avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (<i>Homo sapiens</i>IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -<i>Homo sapiens</i>IGKC*01 (112'-218')]; dimère (227-227":230-230")-bisdisulfure; conjugué, sur 3 à 5 cystéinyl en moyenne, au monométhylauristatine F (MMAF), via un linker maléimidocaproyl (mc) non clivable</p> <p>Pour la partie <i>mafodotine</i>, veuillez-vous référer au document "<i>INN for pharmaceutical substances: Names for radicals, groups and others</i>".</p>
voretuzumab mafodotina	<p>immunoglobulina G1-kappa conjugada con auristatina F, anti-[CD70 de <i>Homo sapiens</i> (miembro 7 de la superfamilia del TNF, TNFSF7, CD27LG, CD27L)], anticuerpo monoclonal humanizado conjugado con la auristatina F;</p> <p>cadena pesada gamma1 (1-448) [VH humanizado (<i>Homo sapiens</i>IGHV1-2*02 (86.70%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -<i>Homo sapiens</i>IGHG1*01 (119-448)], (221-218'-disulfuro (si no está conjugado) con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (<i>Homo sapiens</i>IGKV4-1*01 (79.20%) -IGKJ1*01) [10.3.9] (1'-111') -<i>Homo sapiens</i>IGKC*01 (112'-218')]; dímero (227-227":230-230")-bisdisulfuro; conjugado en 3 -5 restos cisteinil, por término medio, con monometilauristatina F (MMAF), mediante un enlace maleimidocaproyl (mc) no escindible</p> <p>Para la fracción <i>mafodotina</i>, se pueden dirigir al documento "<i>INN for pharmaceutical substances: Names for radicals, groups and others</i>".</p>

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VKKPGASVKV SCASGYTFT NYGMNWRQA PGQGLKWMGW 50
INTYGEPTY ADAFKGRVTM TRDTSISTAY MELSLRSDD TAVYYCARDY 100
GDYGMIDYWGQ GTTVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
FPEPVTVSWN SGALTSQVHT FPAVLQSSGL YLSSVVTVP SSSLGTQTYI 200
CNVNHKFSNT KVDKVEPKS CDKTHCTPPC PAFELLGPGS VFLFPPKPKD 250
TLMISRTPEV TCVVVDVSHE DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
YRVVSVLTIVL HQDNLNGKEY KCKVSNKALP APEKTIISKA KGQPREPQVY 350
TLFPSRDELK KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTPPVLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNHYTQK SLSLSPGK 448

```

Light chain / Chaîne légère / Cadena ligera

```

DIVMTQSPDS LAVSLGERAT INCRASKSVS TSGYSFMHWY QOKPGQPPKL 50
LIYLASNLES GVPDRFSGSG SGTDFLTIS SLQAEDVAVY YCQHSREVPW 100
TFGQGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSPVT KSFNRGEC 218

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

```

Intra-H 22-96 145-201 262-322 368-426
         22"-96" 145"-201" 262"-322" 368"-426"
Intra-L 23'-92' 138'-198'
         23"'-92"" 138"'-198""
Inter-H-L* 221-218' 221"-218"
Inter-H-H * 227-227" 230-230"

```

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
298, 298"

*Two or three of the inter-chain disulfide bridges are not present, the antibody being conjugated to an average of 3 to 5 drug linkers each via a thioether bond.

* Deux ou trois des ponts disulfure ne sont pas présents, l'anticorps étant conjugué à une moyenne de 3 à 5 linker-principe actif chacun via une liaison thioéther.

* Faltan dos o tres puentes disulfuro inter-catenarios por estar el anticuerpo conjugado, con sendos enlaces tioéther, a una media de 3 a 5 conectores de principio activo

zoptarelinum doxorubicinum

zoptarelin doxorubicin


[6-D-lysine]human gonadoliberin-1 (LHRH) and doxorubicin covalently linked together with glutaric acid:
5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L-tyrosyl-*N*⁶-[5-(2-((2*S*,4*S*)-4-[(3-amino-2,3,6-trideoxy- α -L-*lyxo*-hexopyranosyl)oxy]-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-oxoethoxy)-5-oxopentanoyl]-D-lysine-L-leucyl-L-arginyl-L-prolylglycinamide

zoptaréline doxorubicine

[6-D-lysine]gonadolibérine-1 humaine (LHRH) et doxorubicine liées de façon covalente par l'acide glutarique:
5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-séryl-L-tyrosyl-*N*⁶-[5-(2-((2*S*,4*S*)-4-[(3-amino-2,3,6-tridésoxy- α -L-*lyxo*-hexopyranosyl)oxy]-2,5,12-trihydroxy-7-méthoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotétracén-2-yl)-2-oxoéthoxy)-5-oxopentanoyl]-D-lysine-L-leucyl-L-arginyl-L-prolylglycinamide

zoptarelina doxorubicina

[6-D-lisina]gonadoliberina-1 humana (LHRH) y doxorubicina unidas covalentemente mediante ácido glutárico:
5-oxo-L-proliil-L-histidil-L-triptofil-L-seril-L-tirosil-*N*⁶-[5-(2-((2*S*,4*S*)-4-[(3-amino-2,3,6-tridesoxi- α -L-*lyxo*-hexopiranosil)oxi]-2,5,12-trihidroxi-7-metoxi-6,11-dioxo-1,2,3,4,6,11-hexahidrotetracén-2-il)-2-oxoetoxi)-5-oxopentanoil]-D-lisina-L-leucil-L-arginil-L-proliilglicinamida



* <http://www.who.int/medicines/services/inn/publication/en/index.html>

Electronic structure available on Mednet: <http://mednet.who.int/>

Structure électronique disponible sur Mednet: <http://mednet.who.int/>

Estructura electrónica disponible en Mednet: <http://mednet.who.int/>

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Non Proprietary Names (Rec. INN): List 61
Dénominations communes internationales recommandées (DCI Rec.): Liste 61
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 61
(WHO Drug Information, Vol. 23, No. 1, 2009)

p. 53 **bevasiranibum**

bevasiranib
bévasiranib
bevasiranib

replace the description, molecular formula and the structure by the following ones
remplacer la description, la formule moléculaire et la structure par les suivants
sustitúyase la descripción, la fórmula molecular y la estructura por los siguientes

siRNA inhibitor of Vascular Endothelial Growth Factor (VEGF) production;
duplex of adenylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-uridylyl-(3'→5')-cytidyl-(3'→5')-adenylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-adenylyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-adenylyl-(3'→5')-guanylyl-(3'→5')-cytidyl-(3'→5')-adenylyl-(3'→5')-cytidyl-(3'→5')-thymidylyl-(3'→5')-thymidine and thymidylyl-(5'→3')-thymidylyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-adenylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidyl-(5'→3')-cytidyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-cytidyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-guanosine

petit ARN interférant (siRNA) inhibiteur de la production du facteur de croissance de l'endothélium vasculaire (VEGF) ;
duplex d'adénylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-uridylyl-(3'→5')-cytidyl-(3'→5')-adénylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-adénylyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-guanylyl-(3'→5')-cytidyl-(3'→5')-cytidyl-(3'→5')-adénylyl-(3'→5')-guanylyl-(3'→5')-cytidyl-(3'→5')-adénylyl-(3'→5')-cytidyl-(3'→5')-thymidylyl-(3'→5')-thymidine et de thymidylyl-(5'→3')-thymidylyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-adénylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-uridylyl-(5'→3')-cytidyl-(5'→3')-cytidyl-(5'→3')-guanylyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-cytidyl-(5'→3')-guanylyl-(5'→3')-uridylyl-(5'→3')-guanosine

ARN pequeño de interferencia (siRNA) inhibidor de la producción del factor de crecimiento endotelial vascular (VEGF);
dúplex de adenilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-uridilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-guanilil-(3'→5')-citidilil-(3'→5')-adenilil-(3'→5')-citidilil-(3'→5')-timidilil-(3'→5')-timidina y timidilil-(5'→3')-timidilil-(5'→3')-uridilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-adenilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-citidilil-(5'→3')-guanilil-(5'→3')-uridilil-(5'→3')-guanosina

C₄₀₁H₅₀₃N₁₅₃O₂₉₀P₄₀

(3'→5') A-C-C-U-C-A-C-C-A-A-G-G-C-C-A-G-C-A-C-dT-dT
(5'→3') dT-dT-U-G-G-A-G-U-G-G-U-U-C-C-G-G-U-C-G-U-G

Recommended International Nonproprietary Names (Rec. INN): List 63
Dénominations communes internationales recommandées (DCI Rec.): Liste 63
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 63
(WHO Drug Information, Vol. 24, No. 1, 2010)

p. 70	ridaforolimusum	
	ridaforolimus	<i>replace the chemical name by the following one</i>
	ridaforolimus	<i>sustitúyase el nombre químico por el siguiente</i>
		(1 <i>R</i> ,2 <i>R</i> ,4 <i>S</i>)-4-[(2 <i>R</i>)-2- {(3 <i>S</i> ,6 <i>R</i> ,7 <i>E</i> ,9 <i>R</i> ,10 <i>R</i> ,12 <i>R</i> ,14 <i>S</i> ,15 <i>E</i> ,17 <i>E</i> ,19 <i>E</i> ,21 <i>S</i> ,23 <i>S</i> ,26 <i>R</i> ,27 <i>R</i> ,34 <i>aS</i>)-9,27-dihydroxy- 10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo- 1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a- tetracosahydro-3 <i>H</i> -23,27-epoxyprido[2,1- <i>c</i>][1,4]oxaazacyclohentracontin- 3-yl}propyl]-2-methoxycyclohexyl dimethylphosphinate
		dimetilfosfinato de (1 <i>R</i> ,2 <i>R</i> ,4 <i>S</i>)-4-[(2 <i>R</i>)-2- {(3 <i>S</i> ,6 <i>R</i> ,7 <i>E</i> ,9 <i>R</i> ,10 <i>R</i> ,12 <i>R</i> ,14 <i>S</i> ,15 <i>E</i> ,17 <i>E</i> ,19 <i>E</i> ,21 <i>S</i> ,23 <i>S</i> ,26 <i>R</i> ,27 <i>R</i> ,34 <i>aS</i>)-9,27-dihidroxi- 10,21-dimetoxi-6,8,12,14,20,26-hexametil-1,5,11,28,29-pentaoxo- 1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a- tetracosahidro-3 <i>H</i> -23,27-epoxipirido[2,1- <i>c</i>][1,4]oxaazaciclohentracontin-3-il}propil]- 2-metoxiciclohexilo

Recommended International Non Proprietary Names (Rec. INN): List 65
Dénominations communes internationales recommandées (DCI Rec.): Liste 65
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 65
(WHO Drug Information, Vol. 25, No. 1, 2011)

p. 76	obinutuzumabum	
	obinutuzumab	<i>replace the structure by the following one</i>
	obinutuzumab	<i>remplacer la structure par la suivante</i>
	obinutuzumab	<i>sustitúyase la estructura por la siguiente</i>
		Heavy chain / Chaîne lourde / Cadena pesada
		QVQLVQSGAE VKKPGSSVKV SCKASGYAFS YSWINWVRQA PGQGLEWMGR 50
		IFPGDGDYD NGKFKGRVTI TADKSTSTAY MELSSLRSED TAVYYCARNV 100
		FDGYWLVYWG QGTLVTVSSA STKGPSVFPL APSSKSTSGG TAALGCLVKD 150
		YFPEPVTVSW NSGALTSGVH TFFPAVLQSSG LYSLSVVTV PSSSLGTQTY 200
		ICNVNHKPSN TKVDKVEPK SCDKTHTCP CPAPPELLGGP SVFLFPPKPK 250
		DTLMISRTEP VTCVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS 300
		TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV 350
		YTLPPSRDEL TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTTPVL 400
		DSDGSFFLYS KLTVDKSRWQ QGNVFSCSVM HEALHNHYTQ KSLSLSPGK 449
		Light chain / Chaîne légère / Cadena ligera
		DIVMTQTPLS LPVTPGEPAS ISCRSSKSL HSGITYLYW YLQKPGQSPQ 50'
		LLIYQMSNLV SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCAQNLLEP 100'
		YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVCL LNNFYPPREK 150'
		VQWKVDNALQ SGNSQESVTE QDSKDSSTYSL SSTLTLSKAD YEKHKVYACE 200'
		VTHQGLSSPV TKSFNREGC 219'
		Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
		22-96 22"-96" 23'-93' 23"-93" 139'-199' 139"-199" 146-202 146"-202"
		219'-222 219"-222" 228-228" 231-231" 263-323 263"-323" 369-427 369"-427"
		Glycosylation sites / Sites de glycosylation / Posiciones de glicosilación
		H CH2 N84.4
		299, 299" (enriched in bisected non-fucosylated oligosaccharides)

p. 81 **peginesatidum**

peginesatide

péginésatide

peginesatida

*replace the description and the structure by the following ones**remplacer la description et la structure par les suivants**sustitúyase la descripción y la estructura por los siguientes*

pegylated erythropoietin receptor agonist;


$N^{6,21}, N^{6,21}$ -[[$(N^2, N^6$ -bis[[ω -methoxypoly(oxyethylene)]carbonyl)-DL-lysyl- β -alanyl]imino]bis(methylenecarbonyl)]bis[acetylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cysteinyl-L-histidyl-L-methionylglycyl-L-prolyl-L-isoleucyl-L-threonyl-3-(naphthalen-1-yl)-L-alanyl-L-valyl-L-cysteinyl-L-glutaminyll-L-prolyl-L-leucyl-L-arginyl-N-methylglycyl-L-lysineamide] (6 \rightarrow 15:6' \rightarrow 15')-bisdisulfure cyclic

agoniste du récepteur de l'érythropoïétine, pégylé ;

(6 \rightarrow 15:6' \rightarrow 15')-bisdisulfure cyclique du $N^{6,21}, N^{6,21}$ -[[$(N^2, N^6$ -bis[[ω -méthoxypoly(oxyéthylène)]carbonyl)-DL-lysyl- β -alanyl]imino]bis(méthylèncarbonil)]bis[acétylglycylglycyl-L-leucyl-L-tyrosyl-L-alanyl-L-cystéinyl-L-histidyl-L-méthionylglycyl-L-prolyl-L-isoleucyl-L-thréonyl-3-(naphthalén-1-yl)-L-alanyl-L-valyl-L-cystéinyl-L-glutaminyll-L-prolyl-L-leucyl-L-arginyl-N-méthylglycyl-L-lysineamide]

agonista del receptor de la eritropoyetina, pegilado;

(6 \rightarrow 15:6' \rightarrow 15')-bisdisulfuro cíclico del $N^{6,21}, N^{6,21}$ -[[$(N^2, N^6$ -bis[[ω -metoxipoly(oxiétileno)]carbonil)-DL-lisil- β -alanil]imino]bis(metilèncarbonil)]bis[acetilglicilglicil-L-leucil-L-tirosil-L-alanil-L-cisteinil-L-histidil-L-metionilglicil-L-prolil-L-isoleucil-L-treonil-3-(naftalen-1-il)-L-alanil-L-valil-L-cisteinil-L-glutaminiil-L-prolil-L-leucil-L-arginil-N-metilglicil-L-lisinaamida]



Recommended International Non Proprietary Names (Rec. INN): List 66
Dénominations communes internationales recommandées (DCI Rec.): Liste 66
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 66
(WHO Drug Information, Vol. 25, No. 3, 2011)

p. 332 **turoctocogum alfa #**

turoctocog alfa *replace the description, the molecular formula and the structure by the following*
 turoctocog alfa *remplacer la description, la formule moléculaire et la structure par les suivantes*
 turoctocog alfa *sustitúyase la descripción, la fórmula molecular y la estructura por las siguientes*

human coagulation factor VIII-(1-750)-(1638-1648)-peptide compound with human coagulation factor VIIIa light chain, glycosylated des-(751-1637)-human coagulation factor VIII-(1-1648)-peptide containing 92 kDa factor VIIIa heavy chain compound with human coagulation factor VIIIa light chain glycosylated (glycoform alfa produced in CHO cells)

facteur VIII de coagulation humain-(1-750)-(1638-1648)-peptide associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés dès-(751-1637)-facteur VIII de coagulation humain-(1-1648)-peptide contenant la chaîne lourde de 92 kDa du facteur VIIIa associé à la chaîne légère du facteur VIIIa de coagulation humain glycosylés (glycoforme alfa produit par des cellules CHO)

factor VIII de coagulación humano-(1-750)-(1648)-péptido asociado a la cadena ligera del factor VIIIa de coagulación humano, glicosilados des-(751-1637)-factor VIII de coagulación humano-(1-1648)-péptido que contiene la cadena pesada de 92kDa del factor VIIIa asociada a la cadena ligera del factor VIIIa de coagulación humano glicosilados (glicofoma alfa producida por células CHO)

C₇₄₈₀H₁₁₃₈₁N₁₉₉₉O₂₁₉₅S₆₈ (peptide)**Heavy chain / Chaîne lourde / Cadena pesada**

ATRRYYLGAV ELSWDYMQSD LGLEPVDARF PPRVPKSPPF NTSVVYKKTLL 50
 FVEFTDHLFN IAKPRPPWMG LLGPTIQAEV YDTVVITLKN MASHPVSLHA 100
 VGVSYWKASE GAEYDDQTSQ REKEDDKVFP GGSHTYVWQV LKENGPMASD 150
 PLCLTYSYLS HVDLVKDLNS GLIGALLVCR EGS�AKEKTO TLHKFILLFA 200
 VFDEGKSWSHS ETKNSLMQDR DAASARAWPK MHTVNGYVNR SLPLGLIGCHR 250
 KSVYWHVIGM GTTPEVHSIF LEGHTFLVRN HRQASLEISP ITFLTAQTLTLL 300
 MDLQQLLFC HISSHQHDM EAYVKVDSQP EEPQLRMKN EEAEDYDDDL 350
 TDSEMDVVRP DDDNSPSPIQ IRVAKKHPK TWVHYIAAE EDWDYAPLVL 400
 APDRRSYKSQ YLNNQPRIQ RKYKRVFMA YDTEFTKTR EATQHEGSLG 450
 PLYLGEVGD TLLIFKNQAS RPYNIYPHGI TDVRLPYSRR LPKGVKHLKD 500
 FPILPGEIFK YKWTVTVEDG PTKSDPRCLT RYSSSFVME RDLASGLIGP 550
 LLICYKESVD QRCNQIMSDK RNVILFVSVD ENRSWYLTEN IQRFLPNPAG 600
 VQLEDPFEQA SNIMHSINGY VFDLSLQSVL LHEVAYWYIL SIGAQTDFLS 650
 VFFSGYTFKH KMVYEDTLTL PFFSGETVEM SMENPGLWIL GCHNSDFRNR 700
 GMTALLKVSS CDKNTGDYVE DSYEDISAYL LSKNNAIEPR SFSQNSRHFS 750
 QNPPVLRHQ R 761

Light chain / Chaîne légère / Cadena ligera

TRTTLQSDQE EIDYDDTISV EMKKEDFDIY DEENQSPRS FQKTRHYFI 1650
 AAVERLWDYG MSSSPHVLRN RAQSGSVQF KVVVFQFTD GSFTQPLYRG 1750
 ELNEHLGLLG PYIRAEVEDN IMVTFRNQAS RPYSFYSSLI SYEEDQRQGA 1800
 EPRKNFVKPN ETKTYFWKVQ HMAPTKDEF DCKAWAYFSD VDLEKDVHSG 1850
 LIGPLLVCHT NTLNPAHGRQ VTVQEFALFF TIFDETKSWY FTENMERNCR 1900
 APCNIQMEDP TFKENYRPHA INGYIMDTLP GLVMAQDQRI RWYLLSMGSN 1950
 ENIHSIHFSG HVFTVRKKEE YKMALYNLYP GVFEVTEMLP SKAGIWRVEC 2000
 LIGELHAGM STLFLVYSNK CQTPLMASG HIRDFQITAS GQYQWAPKL 2050
 ARLHYSGSIN AWSTKEPPSW IKVDLLAPMI IHGIRKQGAR QKFSLSYISQ 2100
 FIIMYSLDGG KWQTYRQNST GTLMVFFGNV DSSGIKHNIF NPPIIARYIR 2150
 LHPHYSIRS TLRMELMGCD LNCSMPLGM ESKAISDAQI TASSYFTNMF 2200
 ATWSPSKARL HLQGRSNAWR PQVNNPKEWL QVDFQKTMKV TGVTTQGVKS 2250
 LLTSMYKKEF LISSSQDGHQ WTLFFQNGKV KVFQGNQDSF TFPVNSLDPP 2300
 LLTRYLRHHP QSWVHQIALR MEVLGCEAQD LY 2332

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 153-179 248-329 528-554 630-711 1832-1858 1899-1903 2021-2169 2174-2326

Sulfated residues (Y) / Résidus sulfatés (Y) / Restos sulfatados (Y)

Tyr-346 Tyr-718 Tyr-719 Tyr-723 Tyr-1664 Tyr-1680

Glycosylation sites (N_S) / Sites de glycosylation (N_S) / Posiciones de glicosilación (N_S)

Asn-41 Asn-239 Ser-750 Asn-1810 Asn-2118

Recommended International Non Proprietary Names (Rec. INN): List 67
Dénominations communes internationales recommandées (DCI Rec.): Liste 67
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 67
(WHO Drug Information, Vol. 26, No. 1, 2012)

p. 72	mericitabinum	
	mericitabine	<i>replace the chemical name by the following one</i>
	mericitabina	<i>sustitúyase el nombre químico por el siguiente</i> (2' <i>R</i>)-2'-deoxy-2'-fluoro-2'-methyl-3',5'-bis-O-(2-methylpropanoyl)cytidine (2' <i>R</i>)-2'-desoxi-2'-fluoro-2'-metil-3',5'-bis-O-(2-metilpropanoil)citidina

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.